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Background: Myotoxins are a family of small protein toxins present in the venom of 
multiple species of pit vipers that have selective toxic effects on different types of 
tissues. Method: In order to better protect people from these toxins and to potentially 
develop these proteins as the basis for new therapeutics, we investigated the mechanism 
of the cytotoxicity of a specific myotoxin, helleried crotamine (HR-crotamine). Results: 
The results we have obtained demonstrate the specific and selective binding of HR-
crotamine to selected voltage gated potassium (Kv) channels (Kv1.1, Kv1.2, Kv1.3). The 
expression level of these channel proteins correlates positively with the effect of HR-
crotamine on the inhibition of proliferation in multiple cancer cell lines. The binding of 
HR-crotamine to Kv1.3 in Jurkat cells is associated with the inhibition of intracellular 
calcium influx as reflected by the inhibition of NFAT translocation and the inhibition of 
IL-2 secretion. Discussion: These results indicate a direct connection between the 
binding of HR-crotamine to cell surface Kv1.3 channel and the inhibition of cell 
proliferation mediated by the suppression of intracellular Ca2+ signaling. Conclusion: 
We have characterized the cell surface-binding target for HR-crotamine that mediates its 
effects on intracellular signaling. In future studies, the mechanistic model we have 
developed can be used to develop single-chain antibody molecules (scFv proteins) that 
can be used both as molecular probes and HR-crotamine anti-toxins. These antibodies 
may be used to decrease the myotoxin toxicity, which is an important component in the 
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CHAPTER I  
INTRODUCTION OF THE CYTOTOXICITY OF HELLERIED MYOTOXIN 
Introduction and literature review 
The biologic basis for the cytotoxic activity of snake venoms 
Biologic basis 
Snake venom is highly modified saliva("Adult nonfiction: Pure 
sciences,")("Adult nonfiction: Pure sciences,") containing zootoxins that facilitate the 
immobilization of the snake’s prey and its pre-digestion. Snake venoms are also an 
important defense mechanism discouraging future predation by the snake’s natural 
predators (Greenbaum, Galeva, & Jorgensen, 2003).  During a snake bite, venom is 
injected into the prey’s tissues by specialized fangs, although some species of snake are 
also capable of projecting venom as a defensive measure via a spitting mechanism. Most 
snake venoms contain 20 or more different kinds of proteins and polypeptides (Jackson 
et al., 2013). These bioactive proteins and peptides (Greenbaum et al., 2003) either 
immobilize or directly kill the snake’s prey (Weisman, Lizarralde, & Thompson, 1996). 
In addition, enzymatic components of the venom play an essential role in the pre-
digestion of prey facilitating its disintegration once it is ingested by the snake. Snake 
venoms also contain a number of other bioactive proteins and peptides that have 
biological activities that contribute in one way or another to the success of the specific 
species of the snake as a predator (Bottrall, Madaras, Biven, Venning, & Mirtschin, 
2010). The protein constituents in snake venoms impact multiple key biological 




skeletal muscular contractility, the propagation of electrical activity within both the 
central and peripheral nervous systems and the skeletal muscular system. Because of 
their diverse bioactive components and generous volumes, snake venoms have 
frequently served as the starting point for the development of new classes of drugs and 
diagnostic procedures (Luna-Ramirez et al., 2013). 
 
Medical applications of drugs derived from snake venom toxins 
Multiple components of snake venoms from multiple species of snakes have served as 
the starting point for the development of new classes of therapeutics. Small molecule 
therapeutics based on the activity of snake venom toxins have been used for the 
development of treatments for hypertension, thrombotic disease including stroke and 
myocardial infarction, and the treatment of neurological disease including brain injuries. 
Snake venom hemotoxins have been used to develop drugs to prevent heart 
attack and treat blood coagulopathies. The ACE Inhibitors, a class of pharmacologic 
agents, used extensively for the treatment of high blood pressure and other angiotensin-
related diseases, were developed based on the activity of specific snake venom toxins 
(Goodman, Gilman, Brunton, Lazo, & Parker, 2006). Both eptifibatide and tirofiban, 
anti-platelet drugs developed from toxins in rattlesnake and African saw-scaled viper 
venoms, are used to treat pre-infection angina and minor heart attacks. Both of these 
drugs block platelet aggregation and accelerate the dissolution of the blood clots. New 
treatments for stroke patients, based on the activity of a toxin in Malayan pit viper 




Snake venom neurotoxins are being used to develop new drugs for the treatment 
brain and neuronal diseases such as Alzheimer's diseases, Parkinson's diseases, and 
various pain disorders. In addition, drugs derived from snake venom toxins are being 
developed for the treatment of cancer. Some of these toxins interfere with the blood 
supply to tumors tissue often by inhibiting tumor angiogenesis or by disrupting the 
function of tumor-associated endothelial cells (Bridges & Harris, 2015). Other snake 
venom toxins have direct cytotoxicity activity to the tumor cells often by triggering 
lethal signaling pathways. On a completely different track, some components of venom 
have been found to have the significant anti-bacterial and or anti-fungal (Yount et al., 
2009). These toxins are being explored as leads for the development of new classes of 
small molecule antibiotics and antifungal agents.   
 
Molecular basis for the cytotoxic activity of pit viper venoms 
Metalloproteinase, phospholipases   
Recent comprehensive analysis of the transcriptomes presents in snake venom 
gland cDNA libraries have provided a much fuller and unbiased picture of the range of 
toxin molecules that constitute an individual venom.  For instance in an analysis of a 
cDNA library derived from Crotalus adamanteus venom glands (Rokyta, Lemmon, 
Margres, & Aronow, 2012), the authors were able to cluster the transcripts into 78 
groups with less than 1% nucleotide divergence. In this particular snake venom gland 
library, Phospholipase A2-based toxins (PLA2) were among the most functionally 




essential component of many snake and insect venoms, mammalian digestive fluids and 
inflammatory exudates where it leads to degradation of membranes and emulsified lipids 
(Heffernan et al., 2006). Snake venom PLA2’s is a complex family of isoenzymes that 
have been assigned to at least nine sub-groups. These toxins function at membrane 
interfaces cleaving the SN-2 acyl chains from phospholipids and releasing arachidonic 
acid and other biologically active fatty acids. Snake venom PLA2 toxins are have 
biological effects ranging from neurotoxicity to myotoxicity and cardiotoxicity.  
 Metalloproteinases with multiple metalloproteinases and metalloproteinase-like 
proteins are also major components of pit viper venoms. Some of these snake venom 
enzymes are comprised of the metalloproteinase domain only, while others have 
additional disintegrin-like and high cysteine domains. In some snake venom 
metalloproteinases, an additional lectin-like subunit or other subdomains may contribute 
to specific functional activities. All of the venom metalloproteinases with zinc-
dependent enzymes domain have highly similar zinc binding environments.  
 Some snake venom metalloproteinases have direct hemorrhagic activity by 
directly impacting capillary blood vessels, cleaving in a highly selective fashion, key 
peptide bonds of basement membrane components, thereby affecting the interaction 
between the basement membrane and endothelial cells (Rucavado, Escalante, & 
Gutierrez, 2004; Takeda, Takeya, & Iwanaga, 2012). In addition to their hemorrhagic 
activity, venom metalloproteinases also induce myonecrosis and ischemia. Micro vessel 
disruption by metalloproteinases also impairs skeletal muscle regeneration, contributing 




Moura-da-Silva et al., 2008). Venom metalloproteinases contribute to the widespread 
degradation of extracellular matrix components and subsequent prominent local 
inflammatory response that leads to edema and the  activation of endogenous matrix 
metalloproteinases and pro-inflammatory cytokines following snakebite (Fernandes, 
Pereira Teixeira Cde, Leite, Gutierrez, & Rocha, 2007; Markland & Swenson, 2013; 
Rucavado, Borkow, Ovadia, & Gutierrez, 1995). 
 
Myotoxins 
There is some confusion in the field because the term “myotoxin” has been 
applied to two very different types of venom proteins, large homodimeric PLA2- like 
molecules (many that actually lack enzymatic activity) and small, basic peptides related 
to crotamine, a myotoxin isolated from the venom of Crotalus durissus terrificus, a 
tropical South American rattlesnake. Crotamine was the first myotoxin to have been 
isolated and identified and is the mostly intensively studied of the low molecular weight 
myotoxins but several different species of rattlesnakes have been shown to secrete 
crotamine-like myotxins in their venoms. Myotoxins are important components of snake 
venoms because they use non-enzymatic mechanisms to induce muscle paralysis and 
necrosis. Because of the very rapid onset of their activity, myotoxins can cause 
immediate paralysis that prevents the snake’s prey from escaping and leads to its 
eventual death due to diaphragmatic paralysis (Griffin & Aird, 1990; Samejima, Aoki, & 
Mebs, 1991). Most myotoxins appear to act without affecting the integrity of the muscle 




alterations and dilation of sarcoplasmic reticulum (Mamede et al., 2013). Most recent 
studies of crotamine-like myotoxins fall into 7 major categories: gene cloning, protein 
structure analysis, DNA binding mechanism, cell penetration mechanism, cell-specific 
activity, such as anti-tumor, antibacterial and anti-fungal activities and interactions with 
ion channels (Chen, Hayashi, Oliveira, & Karpel, 2012; Cui et al., 2012; Hayashi, 
Oliveira, Kerkis, & Karpel, 2012). 
The crotamine-like myotoxins have generally conserved structures: the total 
length of the peptide is approximately 42 amino acids with three disulfate bonds to 
stabilize the molecular structure. The low molecular weight myotoxin family includes, in 
addition to crotamine (isolated from Crotalus durissus terrificus),  myotoxin A isolated 
from the Crotalus viridis viridis and the hellerid myotoxins (from Crotalus oreganus 
helleri ) that are the subject of this dissertation (Radis-Baptista & Kerkis, 2011; Saviola 
et al., 2015). Crotamine is encoded by the Crt-pl gene that gives rise to a 1.8kb 
crotamine mRNA. Structural studies have shown that the 3D structure of crotamine is 
very similar to that of human beta-defensins (Sanchez et al., 2018). While the molecular 
targets of the crotamine-like myotoxins has not been definitively established, these 
toxins have been reported to affect the electrical activity on multiple types of cells 
pointing to a likely activity against selected ion channels. In addition, a suggested 
analgesic activity of crotamine is reversed by nalozxone, suggesting possible interactions 
with opioid receptors. In addition, crotamine has been demonstrated to penetrate into 





What makes crotamine-like myotoxins particularly interesting 
Medically significant activities of crotamine  
The evolutionary and structural links between the myotoxins and the beta-
defensins has led to their evaluation as anti-microbial agents. Exposure to crotamine kills 
Escherichia coli (Yount et al., 2009) with a very rapid onset (1-2 hr) of activity. This 
anti-microbial activity can be abolished by 12.5 mM NaCl. Interestingly, crotamine’s 
intramolecular disulfide bonds do not appear to be critical for this activity (Nicastro et 
al., 2003) since reduced crotamine works as well as the native protein. The anti-bacterial 
activity of crotamine is quite strain specific, with varying sensitivities the myotoxin was 
also found to have pronounced antifungal activity against several stains Candida spp. 
albicans (Oguiura, Boni-Mitake, Affonso, & Zhang, 2011). 
Crotamine has been of medical interest because of its selective anti-tumor 
activity. Much of this interest has related to its selectivity for proliferating cells and its 
ability both to penetrate cells deliver cargo such as plasmid DNA into the cancer cells 
(Chen et al., 2012; Hayashi et al., 2012; Nascimento et al., 2007).  Others have 
characterized the cytotoxic activity of crotamine against tumor cells both in vitro and in 
vivo. These studies reported that crotamine, at 5 µg/ml (about 1 µM), was lethal to 
several melanoma cell lines but had no activity against normal cells (Pereira et al., 
2011). Twenty-one days of continuous treatment of tumor-bearing mice with crotamine  
(1 g/day) significantly inhibited tumor implantation increasing survival rate and 
decreasing weight loss (Pereira et al., 2011).  Studies that compared tumor cell lines with 




activity for active proliferating tumor cells (Zhang et al., 2006). Crotamine’s 
intracellular localization properties, also showed it to be a potential marker of centrioles 
in actively proliferating cells (A. Kerkis et al., 2004; Oguiura, Boni-Mitake, & Radis-
Baptista, 2005). 
In addition to its anti-tumor activity, crotamine has also been studied for potential 
activity in neurological disease. Low concentrations of crotamine have been shown to 
improve neurotransmission in isolated neuromuscular preparations from myasthenic rats 
by modulating sodium channels. In vivo, in the same animal model, single dose 
treatment with crotamine for 2 weeks resulted in significant improvements in exercise 
tolerance and decreases in the number of fatigue episodes. This study demonstrated that 
low doses of crotamine are highly efficient in enhancing muscular performance in 
myasthenic rats, possibly by improving the safety factor for neuromuscular transmission 
(Hernandez-Oliveira e Silva et al., 2013). 
 
Structural information 
The structure of crotamine has been demonstrated to be closely related to the 
structure of human β-defensin 2 (hBD-2) (Volk, Schwartz, Li, Rosenberg, & Simons, 
1999) (Dalla Valle, Benato, Maistro, Quinzani, & Alibardi, 2012; Whittington et al., 
2008). Beta-defensins, a family of mammalian defensins, have antimicrobial peptides 
that contribute to the resistance of epithelial surfaces to microbial colonization. Their 
mass ranges from 2-6 kDa, they are all highly cationic and show activity against many 




Wimley, & Selsted, 1995). The beta-defensins typically have three intramolecular 
disulfide bonds that stabilize their structure. On the basis of their size and pattern of 
disulfide bonding, mammalian defensins are mainly classified into alpha, beta and theta 
categories. In human, rabbit and guinea pig, the β-defensins induce the activation and 
degranulation of mast cells, resulting in the release of histamine and prostaglandin D2.  
Similar to other defensins, β-defensins are cationic and, therefore, can interact with the 
negatively charged membrane of invading microbes. Based on its electric charge, beta-
defensin peptides can insert directly into the bacterial membrane (van Dijk, Veldhuizen, 
& Haagsman, 2008) and establishing pore complexes that cause membrane 
depolarization and cell lysis (van Dijk et al., 2008). Based upon its similarity with the 
structure of beta-defensins, crotamine has been projected to have similar binding 
behavior to microbial membranes. There are however significant differences in the 
properties of the two classes of molecules  (Dalla Valle et al., 2012; Yount et al., 2009) 
based on the fact that  hBD-2 does not penetrate normal mammalian cell membranes 
whereas crotamine does.  
 
Proposed mechanisms of action 
To better understand the properties of crotamine, we have collected information 
from a wide variety of published studies. Current research on crotamine and crotamine-
like myotoxins have been focused on the following areas: 1) In vitro studies  of 
crotamine’s cell-specific cell penetration activity (Nascimento et al., 2007; Sieber, 




crotamine and the induction of apoptosis (Pereira et al., 2011); 3) crotamine’s effects on  
ion channel conductance through interference of Kv channel activity; 4) the selective 
accumulation of administered crotamine in cancer tissue, in vivo; and 5) transient effects 
of crotamine on intracellular calcium kinetics.  
 
Cell-penetrating and DNA binding activity 
Several groups have investigated the cell penetrating activity of crotamine and 
similar myotoxin, however, the conclusions of these studies are controversial. The most 
commonly held theory is that crotamine interacts with heparan sulfate proteoglycans on 
the surface of susceptible cells. Normal endocytic processes the deliver the crotamine 
into the interior of the cell leading to accumulation of the cationic peptide within the 
acidic endosomal vesicles. In a final step, the contents of the vesicles leaks to the cell 
cytosol due to the permeabilization of endosomal membranes (Ownby, Gutierrez, 
Colberg, & Odell, 1982). In addition to crotamine, snake venom myotoxin I and 
myotoxin II have been evaluated for the effect of altering membrane lipid content on 
their cytotoxic in C2C12 myoblast cells. These studies demonstrated  that the cytolytic 
activity of both myotoxin I & II was increased in cholesterol-depleted membranes 
whereas the cytolytic activity of myotoxin II was decreased in direct proportion to a 
lowering of the temperature, implicating membrane fluidity in the process (I. Kerkis, 
Silva Fde, Pereira, Kerkis, & Radis-Baptista, 2010). Similar results were obtained by 
Santos N.C. who demonstrated that crotamine can cross lipid bilayer membranes even in 




reports from other labs that crotamine can interact with lipid bilayers and can potentially 
penetrate cells via a variety of entry mechanisms (Hayashi et al., 2008; Nascimento et 
al., 2007). 
Crotamine also has DNA binding activity and has been explored as a 
nanoparticle delivery system capable of delivering dsDNA, ssDNA and siRNA into the 
cell both in vivo and in vitro condition (Hayashi et al., 2012). When crotamine binds to 
DNA, the peptide occupies a span of about two and a half nucleotide pairs, so that about 
four crotamine molecules bind within a 10bp turn of a B-DNA helix. Salt sensitivity 
studies indicate a maximum of three ionic interactions between the protein and DNA 
(Mandal et al., 2012). These constraints assign the DNA binding activity of crotamine to 
the positive charges on the C-terminus of crotamine molecule. Detailed analysis of the 3-
D structure of the C-terminus, suggest that five residues in positions 31 to 35, Arg-Trp-
Arg-Trp-Lys are the putative DNA-binding site. The actual delivery of DNA into cells 
depends on the aggregation and precipitation of crotamine-DNA complexes at low ionic 
strength and their subsequent cellular uptake. This mechanism explains the preference 
for long chain over short chain DNA molecules for crotamine-mediated cellular delivery 
(Chen et al., 2012). 
 
Ion channel activity 
Voltage-dependent ion channels are members of the voltage-dependent cation 
channel family, which includes the voltage-dependent K+, Na+, and Ca2+ channels 




Kv channel activity and thereby change resting membrane potentials. The Kv channels 
are found in both eukaryotic and prokaryotic cells. The intact Kv channel is comprised 
of  four identical protein subunits that associate to form a four-fold symmetric complex 
arranged around a central ion-conducting pore (Orlova, Papakosta, Booy, van Heel, & 
Dolly, 2003). The TM, T1 and β domains (from extracellular to intercellular) in each 
subunit defines the basic structural organization of the channel protein. Critical 
components of all K+ channels include the conserved structures that serve as the K+ 
selectivity filter on the extracellular side of the pore; the inner pore varies in its 
confirmations among different members of the family (Doyle et al., 1998). The β-
domain plays a vital role in the regulation of channel activity. The intact channel 
includes four beta subunits, auxiliary proteins that associate with alpha subunits in a one-
to-one stoichiometry (α4β4) (Pongs et al., 1999).   
Voltage-gated Kv1 channel plays a critical role in regulating resting membrane 
potential, action potential duration and neurotransmitter release in mammalian neurons. 
The activity of Kv1.3 channel has been most extensively investigated in the function of 
T-lymphocytes (Ouadid-Ahidouch & Ahidouch, 2008; Ouadid-Ahidouch, Roudbaraki, 
Ahidouch, Delcourt, & Prevarskaya, 2004; Pardo, 2004; Wonderlin & Strobl, 1996) 
where its activity has been linked to progression through the G1 phase of the cell cycle. 
Studies in multiple cell lines, have demonstrated that the expression of Kv1.3 channels 
appear to be cell cycle-dependent and seems to contribute activity in both S and G1 
phase of the cell (Chittajallu et al., 2002). Kv1.3 inhibitors have been considered to have 




the potential role of Kv channels as targets for the development of new anti-tumor 
therapies. The Kv1.5 channel, and to a lesser extent the Kv1.3 channel are aberrantly 
expressed in a number of human cancers (Bielanska et al., 2012; Bielanska et al., 2009; 
Ouadid-Ahidouch et al., 2000; Zhou, Unlap, Li, & Ma, 2002).  
  There is evidence that a number of snake venom toxins target Kv channel 
activity. Dendrotoxins, components of Mamba venoms, are potent Kv1.1 channel 
inhibitor, that have been used extensively to profile the structural determinants of Kv 
channel activity. Myotoxins have also been implicated as Kv channel modulators. Patch 
clamp studies with crotamine have shown selective inhibition of some but not all Kv 
channels (Kv1.1, Kv1.2, Kv1.3 but not Kv 1.5) (Mouhat, Andreotti, Jouirou, & Sabatier, 
2008; Mouhat, Jouirou, Mosbah, De Waard, & Sabatier, 2004).  
In addition to its effects on Kv channels, myotoxins such as crotamine have also 
been reported to modify the activity of voltage-sensitive Na+ channels in both muscle 
and mast cells (Toyama et al., 2000). Crotamine increases the Na+ conductance of 
skeletal muscle membranes, an effect that can be blocked by tetrodotoxin. Crotamine 
induced depolarization of myocytes was investigated using an improved loose patch-
clamp technique; and a dose-dependent curve with an EC50 of 0.15 µg/ml was observed 
(Matavel, Ferreira-Alves, Beirao, & Cruz, 1998). These studies suggest either that 
crotamine is increasing the number of functioning Na+ channels or increasing the 
number of channels that are in the “open” state during membrane depolarization. 





Heparan sulfate proteoglycans (HSPG) binding 
Many snake venom toxins have an affinity for HSPGs, a property that 
presumable enhances their association with cell membranes and facilitates their 
interactions with specific membrane receptors. Myotoxins in particular bind due HSPG’s 
because, as strongly cationic peptides they have a high affinity for the negatively-
charged HS-side chains of the HSPG’s (A. Kerkis et al., 2004). In the case of crotamine, 
the direct binding to HSPG’s appears to facilitate the cell-penetrating activity of the 
peptide. There is a direct correlation between the level of the HSPG’s expressed on the 
surface of different types of cells and their vulnerability to penetration by crotamine. 
 
The goal of this project 
Hypothesis 
The goal of our study is to identify the cellular and molecular basis for the 
selective inhibitory effect of snake venom myotoxins, on the proliferative activity of 
certain types of cancer cells. Although we consider a full range of possibilities for the 
molecular basis of this activity, based on evidence drawn from the literature, we tested 
the hypothesis that crotamine binds specifically to certain Kv channels expressed on the 
surface of cancer cells and that the binding of the toxin to this target results in molecular 






Goals – identify the cell surface binding target for crotamine and understand the 
intracellular mechanism of its effect.  
To achieve the goal of our study, we have divided our research into the following 
steps: 
1) To investigate whether Kv channels on cancer cells are the target for the 
anti-proliferative activity of crotamine. This involve: a) investigation of the specific 
binding of crotamine to Kv channels expressed on the surface of crotamine sensitive 
cells; b) determination of the effect of the binding of crotamine to specific Kv channels 
on the surface of susceptible cells results in an inhibition of cellular proliferation. 
2) To establish the molecular mechanism for the target dependent effect of 
crotamine on the proliferative activity of sensitive cells. This involve: a) characterization 
of the cellular mechanisms involved in the anti-proliferative activity of crotamine; b) 
characterization the intracellular mediator of the anti-proliferative activity of crotamine.   
 
Materials and Methods 
Sequence analysis 
The sequences of helleried crotamine (HR-crotamine) isolated from Crotalus 
oreganus helleri and crotamine (isolated from Crotalus durissus terrificus) [Fig. 1] were 
aligned and investigated for the similarity. There are seven of the full-length amino acid 
sequences, identified with the codenames 5J11, 3M19, 6O01, 5C09, 1l06, 1N24, 5i03. 





Source of cell lines – validation 
Cancer cell lines (REN, HeLa, HeLa NFAT 1-460, HEK293T, CCRF CEM) 
were obtained from Center of Translational Cancer Research, Texas A&M Institute of 
Biotechnology (IBT). The B16-F10 cell line was provided by Dr. DeKai Zhang lab in 
IBT, the Mia PaCa-2 cell and Jurkat cell lines were obtained through collaborative labs 
in University of Texas MD Anderson Cancer Center, and the C2C12 cell line was 
obtained from Baylor College of Medicine (BCM). The SK-Mel-28 cell was obtained 
from Dr. Bartholomeusz’s, (MD Anderson Cancer Center) and the Molt-3 cell line was 
obtained from Dr. Lacorazza, in Texas Children Hospital. All cell lines were cultured 
under the condition listed in Table 1. 
 
Source of myotoxins – characterization 
The myotoxin used in these studies was isolated from the venom of Crotalus 
oreganus helleri by High-Performance Liquid Chromatography (HPLC). [Fig. 2] The 
diluted venom was injected into the ion exchange column, and the expected fraction of 
the 6th elution peak was collected and lyophilized for stock. After a desalting step, the 
sample was resuspended in PBS. The FITC labelling was accomplished by direct 
conjugation to HR-crotamine using the DyLight 488 antibody labeling kit (Thermo 





Fig. 1. The HR-crotamine used in our study is isolated from the venom of Crotalus 
oreganus helleri 
Crotamine is isolated from the venom of Crotalus durissus terrificus. 
 
Table 1. Cell Culture Conditions for the Cell Lines Used in Our Study. 
 
 
Cell line Source tissue Medium Condition 




adenocarcinoma cell line 
engineered to contain and an 
NFAT reported system 
DEME, 10%FBS, 1%100xGluMax,1%HEPES, 
1%Sodium Pyruvate 37°C, 5% CO2 
HeLa Human cervical adenocarcinoma cell line 
DEME, 10%FBS, 1%100xGluMax,1%HEPES, 
1%Sodium Pyruvate 37°C, 5% CO2 
C2C12 Mouse myoblast cell line DEME, 10%FBS, 1%100xGluMax,1%HEPES, 1%Sodium Pyruvate 37°C, 5% CO2 
Jurkat Human T cell leukemia cell line RPMI-1640, 10%FBS, 1%100xGluMax 37°C, 5% CO2 
HEK293T Human Embryonic Kidney cell line 293 
DEME, 10%FBS, 1%100xGluMax,1%HEPES, 
1%Sodium Pyruvate 37°C, 5% CO2 
B16-F10 Mouse melanoma cell line  DEME, 10%FBS, 1%100xGluMax,1%HEPES, 1%Sodium Pyruvate 37°C, 5% CO2 
SK-mel-28 Human melanoma cell line DEME, 10%FBS, 1%100xGluMax,1%HEPES, 1%Sodium Pyruvate 37°C, 5% CO2 
Mia PaCa-2 Human pancreatic adenocarcinoma cell line 
DEME, 10%FBS, 1%100xGluMax,1%HEPES, 
1%Sodium Pyruvate 37°C, 5% CO2 
Molt-3 Human T cell leukemia cell line RPMI-1640, 10%FBS, 1%100xGluMax 37°C, 5% CO2 






Fig. 2. HPLC Cation Exchange Fractionation of Southern Pacific Rattlesnake 
(Crotalus oreganus helleri) venom  
Crude venom (10 mg) from Southern Pacific Rattlesnake (Crotalus oreganus helleri) 
was first bound to the HPLC column in an equilibrating buffer (0.02 M Tris-HCl, 
pH=8.0) and eluted with a gradient of increasing 0.5 M NaCl. HR-crotamine was eluted 
when the elution buffer reaches 100%. The total running time is 90 min. 
 
 
Cell viability assays 
At time 0, individual cell lines were seeded into 384-well plates at a density at 
1000 cells/well using a Multidrop dispenser with low spray speed to ensure the even 
distribution of the cells. All cell growth determinations were performed in quadruplicate. 
After the dispensing of the cells, the plates were shaken for 10 min to avoid an uneven 
distribution of the cell in the wells. After overnight incubation, the HR-crotamine or 
other test substances were added to the cells in half-fold gradient concentration from 0-




washing with PBS twice. The cells were permeabilized by the addition of 0.5% Triton-
X100, for 10 min and then treated with 1 µg/mL DAPI for 10 min for visualization.  The 
test plates were imaged in an InCell 6000 high-throughput confocal fluorescent 
microscope with DAPI filter at 4X power. The images from individual wells were 
analyzed based on nuclear segmentation and counting using InCell Developer. An IC50 
was calculated for each of the test substances added to the wells and for each of the cell 
lines tested.  
For CellTiter-Glo determinations (measure of total ATP content), cells were 
seeded into 384-well plates at an appropriate cell density. Each determination was 
performed in a quadruplicate to ensure the reliability and accuracy of the values 
obtained. The seeded cells were cultured with the presence of HR-crotamine, PBS 
(negative control) and Etoposide (positive control) for 72 hr. The HR-crotamine and 
Etoposide were added in a half fold linear dilution gradient with the highest 
concentration at 800 nM and 100 µM, respectively. At the end of the experiment, the test 
plate was centrifuged and the volume of media was reduced to 15 µl. The CellTiter-Glo 
reagent was added at 1:1 ratio with the residual volume. After 45 min of incubation, 
luminescence intensity was determined using a plate reader. The values obtained were 
analyzed for growth inhibition, compared to the negative control. In the metabolism rate 
test, cells were seeded in gradient density and then incubated with HR-crotamine for 72 






Cytotoxicity kinetics test 
C2C12, HEK293T, HeLa, SK-Mel-28 cells and Jurkat cells were seeded in a 384 
well plates. The test substances (0.02% SDS or HR-crotamine in 8-half fold dilutions 
from 1 µM) were added for 0.5, 2, 24 and 72 hr and cell viability and the number of dead 
cells was determined using Hoechst 33342 and DRAQ7 staining (Thermo Fisher 
Scientific and Biostatus, respectively). PBS served as the negative control. DRAQ7 
staining was observed through the Texas Red channel with a 4X objective. The images 
were processed and compared using the InCell Developer. 
 
Transcript and protein profiling studies 
Gene-specific PCR assay and Real-time PCR analysis 
Total mRNA was extracted from cells with the Qiagen RNeasy Mini Kit and 
according to instructions provided by the manufacturer. Briefly, adherent cells in 10 cm 
dishes (approx. 2.5-10 x 106 cells per dish) were lysed directly in the culture dish after a 
PBS wash. Cells growing in suspension were pelleted by centrifugation for 5min at 500 
x g and washed once with PBS prior to lysis. An appropriate volume of RLT buffer is 
added, cells are resuspended by vortexing and then lysed by passage through a 20-gauge 
needle fitted to an RNase-free syringe for 5-10 times. The same volume of 70% ethanol 
is added to the lysate and mixed by pipetting. Seven hundred microliters of the samples 
are then transferred to an RNeasy spin column placed in a 2 ml collection tube and 
centrifuged for 30s at 8,000 x g.  After discarding the flow-through and 700 µl of buffer, 




8,000 x g. RPE buffer (500 µl) is added to the RNeasy spin column and the column is 
centrifuged for 30s at 8,000 x g. The flow-through is also discarded. This step is 
repeated once with an additional 2 min of centrifugation time added to the repeat. The 
RNeasy spin column is placed in a new 1.5 ml collection tube and the total RNA is 
eluted by 30-50 µl RNase-free water or elution buffer by centrifugation for 1 min, at 
10,000 x g.  
Reverse transcript synthesis was accomplished with the SuperScript III first-
strand synthesis system. Total mRNA from a specific cell sample is combined with 
primer and buffer that includes Oligo(dt)20 1 µl, dNTP 1 µl, RNA solution 5 µl, and 
molecular grade water 3 µl for a final volume of 10 µl. The samples are heated to 65oC 
for 5 min in Bio-rid thermal cycler followed by cooling down on the ice for 1 min. Then, 
10 µl of cDNA synthesis Mix (10x RT buffer 2 µl, MgCl2 4 µl, 0.1 M DTT 2 µl, 
RNaseOUT 1 µl and SuperScript III RT 1 µl) was added to the chilled samples. The 
samples are then heated to 50oC for 50min and 85oC for 5 min. 1 µl of RNase H was 
added to the sample and incubated at 37oC for 20 min. The samples were then ready for 
the PCR analysis and were stored at -20oC. 
Gene-specific PCR was used to confirm the expression of the Kv1.1, Kv1.2, 
Kv1.3 and Kv1.5 transcripts as well as the specificity of the gene-specific primers for 
real-time PCR analysis. The sequences of primers used in this study are listed in the 
Table 2. The PCR mix was made in a 20 µl reaction system, which includes 10x PCR 
buffer 2 µl, MgCl2 1 µl, forward primer 1 µl, reverse primer 1 µl, dNTP 1 µl, Template 




protocol: the initial denaturation is at 95oC for 5 min, followed by 40 cycles of 
amplification. Each cycle includes 95oCfor 30sec; different annealing temperatures were 
tested (55oC, 50oC and 47oC for 30sec.) and then 72oC for 30sec. The final extension 
was performed at 72oC for 3min followed by a cool-down step to room temperature.  
The PCR product was analyzed on a 2% agarose gel, and DNA was visualized by UV 
illumination. [Fig. 3] 
 







Fig. 3.  The processes of sample preparation for both real time qPCR and the 
ELISA analysis of cell membrane proteins 
 
i. SDS-PAGE and Western blot 
For cell membrane protein preparation, cells were washed with PBS and then 
lysed with a digitonin lysis cocktail with protease inhibitor. The lysate was centrifuged 
at 500 x g to remove the DNA and another cellular debris released in the supernatant. 
The pellets were digested in 0.5% Triton-X100 lysis buffer with the protease inhibitor 
(shaken on ice for 30 min) and the pellets were removed by centrifugation at 10,000 x g 
for 5 min. The protein concentration of the supernatant was measured using the Bradford 
assay. Briefly, samples were diluted 10-20 fold and mixed with Bradford assay buffer 
(Coomassie blue G-250) and the absorbance at 600 nm was read and used to calculate 




and mixed with 5 µl of 5x SDS-PAGE sample loading buffer. The samples were heated 
to 95oC for 5 min and loaded onto the SDS-PAGE gels. Electrophoresis was at 150 volts 
for 50 min. Proteins on the gel were transfer to a PVDF membrane with a Bio-Rad mini 
trans system.  The membrane was blocked with 5% non-fat milk for 2 hr. The Kv1.3 
protein was detected by rabbit anti-Kv1.3 antibody (1:200) for 1 hr and HRP-conjugated 
anti-rabbit secondary antibody (1:500) for 1hr. After washing the membranes with TBST 
buffer (Tris buffer, 0.5% Tween-20) 3 times, 15 min each time, protein was visualized 
by Immobilon Western Chemiluminescent HRP Substrate. 
 
The cell surface staining and cell imaging of Kv1.3 channel expression 
Experiments were performed in glass bottom 96-well plates with 500 cells per 
well seeded at Day 0. After overnight incubation, the media was removed and the cells 
were fixed with 4% PFA after washing twice with PBS. Non-fat milk 5% in TBST 
buffer was added into the wells for 2 hr after washing removed the PFA; and proteins 
was detected with rabbit anti-Kv1.3 channel antibody (1:200) or FITC direct conjugated 
rabbit anti-Kv1.3 antibody for 2 hr.  If the unconjugated antibody was applied, then an 
extra secondary antibody incubation step with donkey anti-rabbit antibody was needed.  
After washing 3 times with TBST buffer, fluorescent antibody staining was visualized 








Kv channel clone and recombinant expression 
The Kv1.1 channel, Kv1.2 channel, Kv1.3(truncated and full sequence) channel 
and the Kv1.5 channel was cloned into a eukaryotic expression vector with an mCherry 
fusion protein at the C-terminal of fusion protein. [Fig.4] The specific primer with an 
adapter sequence was designed for each gene. [Table 3] 
 
 
Fig. 4. The vector map for the pcDNA3 expression vector  
The pcDNA3 mCherry LIC cloning vector (6B) was utilized for the overexpression of 
the Kv channels in cells. With a CMV promoter, a mCherry florescent tag can be fused 







Table 3. The vector compatible gene specific cloning primers are listed in the table  
The Kv1.3 truncated primer can be used to amplify the truncated Kv1.3 gene, in which 
first 52 residues are deleted from the full-length molecule
 
 
The gene specific sequences for the Kv1.1 channel, Kv1.2 channel, truncated 
Kv1.3 channel cDNA’s were cloned from other non-expression vectors and the Kv1.3 
full-length channel and Kv1.5 channel cDNA’s were cloned from a cDNA pool made 
from the reverse transcription of Jurkat cell total mRNA. The total mRNA extraction 
procedure was the same as the protocol described above and the primers used are also 
listed in the Fig. 3. The PCR reaction was designed with longer extension time to ensure 
the quality of the PCR product. After confirmation of the cloning with 1.5% agarose gel 
electrophoresis, the PCR product was purified by QIAquick Gel Extraction kit (Qiagen, 
Mo). The restriction enzyme digested PCR product was re-purified by the gel 
electrophoresis. The ligation was transferred into competent E.coli (BL21) using a 
transfection protocol based on heat shock for 40 seconds followed by cooling on the ice 
for 30 min. 
Transfected E.coli were cultured at 37oC for overnight on an orbital shaker, 225 
rpm. The E.coli were harvested by centrifugation at 10,000 x g and the plasmid was 




provided by vendor. After the final steps, the plasmids concentration was determined 
using the NanoDrop™ Lite Spectrophotometer to ensure a final concentration that is 
above 200 ng/µl. The cloning results were confirmed by both PCR-gel electrophoresis 
and sequencing; the insert was amplified by gene-specific primers, and the length was 
confirmed by gel electrophoresis. The CMV and mCherry primers were used to 
sequence the insertions. 
The transfection protocol was optimized to identify the best combination of 
conditions for the highest efficiency of transfection. HeLa cells were seeded into 384 
well plates before the experiment. A gradient concentration of lipofectamine 2000, (from 
2 times to 1/8 times of recommended dosage), was tested to determine the level giving 
70-90% fusion. Different doses of input DNA was also tested. The detailed protocol 
used was the one recommended by the vendor. Briefly, 100-800 ng of plasmid DNA was 
mixed with 5 µl Optimal DMEM media and the 0.0125-0.125 µl of lipofectamine 3000 
was also dissolved into 5 µl of Optimal DMEM media. After mixing the lipofectamine 
3000 and plasmid DNA for 30 min, the mixture was added to the well and the 
transfected cells were cultured for 48 hr to allow for the accumulation of the expressed 
protein.  At the end of the incubation, cells were fixed and permeabilized with 4% PFA 
and 0.5% TritonX-100. After staining with DAPI, images were collected using an InCell 







Surface and intracellular staining of cells with FITC conjugated HR-crotamine 
Forty-eight hours after the transfection, HEK293T or Jurkat cells (on poly-D-
lysine coverslip or 6 wells-plate) were fixed and washed twice with PBS. To test 
intracellular staining, cells were permeabilized with 0.5%v/v of Triton-X100 buffer for 
15 min. The cells were then blocked with 5% low-fat milk (or 5% BSA) for 2 hours at 
room temperature. FITC labeled HR-crotamine (300 nM-10 µM) was added to the 
blocking buffer and applied to the cells for 1 hr at room temperature followed by 
washing with TBST buffer 3 times. Coverslips were then used for fluorescent imaging 
and the cells in the 6 wells plates were scraped and suspended for flow cytometry 
analysis.  
 
Enzyme digestion studies 
Enzyme digestion studies were based on the Heparinase III (New England labs 
Inc., MA) digestion of the HSPG on the surface of cultured cell lines. Different cell lines 
were treated following a published protocol (Welch, Svensson, Kucharzewska, & 
Belting, 2011). Specifically, cells were cultured in 12 well plates or coverslip at 70-80% 
confluence. Cells were then washed with PBS and treated with the enzymes. The 
Heparinase III digestion buffer contains 20 mM Tris-HCl, 100 mM NaCl, 1.5 mM 
CaCl2, pH 7 and 2% FBS. The concentration of the Heparinase III was 10 units/ml. The 
reaction condition involved incubating cells in 37oC cell incubator for 3 hr followed by 




Trypsin (Sigma-Aldrich, MO) was used as positive control; and the digested cell were 
stained for FACS or microscopy studies.  
 
Results 
Specificity - Comparison of myotoxins 
Crotamine versus helleried crotamine 
The amino acid sequences of crotamine and helleried crotamine (HR-crotamine) 
have been aligned and compared. The alignment demonstrated about 90% of the residues 
are identical. A few sites of heterogeneity were also identified. In these aligned 
sequences, both proteins include a 22 amino acids signal peptide at the N-terminus. 
Overall amino acid sequences are highly with at least 36 of the 42 amino acids residues 
shared between the two proteins. Both sequences contain 11 basic amino acids, 9 lysins, 
and 2 arginines, and 6 cysteines. The cysteines generate 3 intramolecular disulfide-bonds 
that help maintain its 3-D structure of the protein. The 3-D structure of both myotoxins 
is very similar to that of human beta-defensins, important components in the mammalian 
innate immunity system. Based on the deduced amino acids sequences of both proteins, 
we have a calculated molecular weight of 4905.96 Da and pI point of 9.51. The molecule 
is highly positive charged cationic peptide, which contains 7e+ positive change in at 
physiological pH.  The amino acids sequence of our HR-crotamine was obtained and 
confirmed with mass spectrometry and the peptide was observed to have an actual 
molecular weight at 4858.575 Da. [Fig.5 A] Counting from the first amino acid of the 




including Arg3 vs Gln3, Leu19 vs Ile19, Arg33 vs Lys33, and Glu42 Lys43 vs Val42 Asn43. 
Some of the isoforms of HR-crotamine have variations at the 15th and 16th residue (Glu15 
Lys16 vs Thr15 Val16) and a C-terminal extension that is several residues longer than the 
published crotamine sequence. The corresponding cDNA sequences for those amino acid 
differences were also compared. Only one base pair switch is required to explain the 
differences between Arg3 vs Gln3, Leu20 vs Ile20. In contrast, some other isoforms, such 
as the Glu15Lys16 vs Thr15Val16 and the C-terminal extension requires significant 
differences in the encoded gene sequences. Based on the molecular weight 
determinations, HR-crotamine (6O01) was believed to have a 7 amino acids truncation at 
C-terminal end of the molecule. The major differences in sequences were considered as 
reflecting evolutionary changes rather than simple point mutation in the individual 
genes. Since there is strong homology between crotamine and HR-crotamine and there 
are only minor differences in their amino acid sequences, we have felt comfortable using 
HR-crotamine as a probe to investigate the molecular properties of snake venom 
myotoxins. We have based our studies of HR-crotamine on the results obtained by others 
in the previous investigation of the activity crotamine isolated from C. durrisus terrificus 





Fig. 5. The protein sequence and structure of helleried crotamine   
A) CID spectra of HR-crotamine. The CID spectrum of peptides KGGHCFPKEK (m/z 
1187.590), EKICIPPSSDFGKMDCR (m/z 2056.930). The characteristic peptide bond 
fragment ions, type b and type y, are labeled. In the lower panel, the chart indicating an 
accurate mass measurement of the HR-crotamine peptide using CytC as a calibrant in 










(Fig. 5 Continued) 
 
 
B) The alignment presenting the comparison of the amino acids sequences between the 
HR-crotamine from Crotalus oreganus helleri and the published crotamine sequence 
(from Crotalus durissus terrificus). A 22 amino-acids signal sequence at N-terminus is 
marked out in black box and the HR-crotamine’s residue that heterogeneous to 
crotamine’s are labeled in red and green. A tail sequence (in blue) at C-terminus can be 
recognized on HR-Crotamine and other 3 similar HR-crotamine molecules. A 7 amino 
acids truncation at C-terminal of the 6O01molecule is marked in blue box. C) The 3-D 
structural model for both crotamine and HR-crotamine were calculated and predicted 
according to the amino acid sequences The helical ribbons: α-helices and β-strands the 
direction of the chain are marked; and each structure are compared in front, side and 
bottom view (related by180-degree rotation through the x and y axis). The high 
similarity for the structure of these two molecules are recognized. 
 
Dose-dependent effect of crotamine / HR-crotamine on cell proliferation and cell 
viability – IC50 Table 
Previous patch clamp studies with crotamine have indicated that crotamine 




HR-crotamine, we applied HR-crotamine to a panel of different cancer cell lines 
including REN, HeLa, HEK293, B16-F10, MIA PaCa-2, SK-Mel-28, Jurkat, Molt-3, 
CCRF CEM cells and mouse myoblast cell, C2C12. Information on these cell lines are 
listed in Table.1. HR-crotamine in a half fold dilution gradient was applied to each of the 
cell lines and the cell viability was investigated with DAPI staining. The test, which was 
conducted in quadruplicate (n=4), was conducted using the high throughput liquid 
dispensing robot. The standardized results obtained are summarized in a dose -dependent 
chart of growth inhibitory activity for each of the cell lines tested. [Fig.6 A] The results 
are expressed as growth inhibition, or cell death percentage compared with the number 
of cells at the starting point of the experiment and the growth of the negative control 
population during the course of the experiment (72 hr in our tests). The differences in the 
sensitivity of different cell lines to the growth inhibitory effects of HR-crotamine 
suggests that cells with higher sensitivity to the myotoxin may have higher levels of a 
receptor that mediates HR-crotamine’s activity on cell proliferation. 
The results of this experiment indicated that Jurkat cells are the most sensitive 
and HeLa cells are the least sensitive of the cell lines tested to the growth inhibitory 
effects of HR-crotamine. The significant differences between these two cell lines in 
effective concentration of HR-crotamine required to produce growth inhibition reflects 
the notable cell-specific selectivity for HR-crotamine’s toxicity and suggests that there 
may be a specific receptor, or target, in Jurkat cell that mediates the effects of HR-
crotamine. However, because of HR-crotamine’s potential cell penetrating activity, this 




crotamine receptor located at the cell surface. An alternative explanation is that the 
mechanisms for HR-crotamine’s activity on Jurkat versus HeLa cells may be different 
and that this explains the large differences in the EC50’s. HR-crotamine could have 
multiple receptors at the cell surface or/and intracellular sites.    
 
Fig. 6. The effects of HR-crotamine’s on cell proliferation  
A) The anti-proliferative effect of HR-crotamine on multiple cancer cell lines Each 
experiment was performed in 4-6 replications with means and curve fitting trend line 




(Fig. 6. Continued) 
REN, HeLa, C2C12, HEK293T, B16-F10, SK-Mel-28, MIA PaCa-2, CCRF-CEM, 
Molt-3 and Jurkat cells were incubated with graded concentrations of HR-crotamine for 
72 hours. Cell numbers were measured by DAPI image segmentation and were 
expressed as percent (%) for growth/death of control.  B) The cell growth inhibitory 
effect of FITC labeled HR-crotamine The chart indicates the cell proliferation was 
inhibited while the graded concentration of HR-crotamine was present. The PBS was 
used as the negative control. The positive control is cells treated with Etoposide. Each 
data point is the mean+/-standard deviation, calculated from 4 replicated determination.  
The curve was fitted based on each data point with least square method. C) The heatmap 
for the IC50 of HR-crotamine on multiple cell lines After the application of the growth 
inhibition test in multiple cell lines, the growth curve for HR-crotamine with graded 
concentrations was obtained. The IC50 for each cell line was obtained from the curve 
fitting procedure. Due to the significant range of IC50’s, the logarithmic IC50 was use to 
generate the heat map. 
 
We compared the activity of HR-crotamine and FITC conjugated HR-crotamine 
to confirm that they have similar activity. Using the cell viability assay described above, 
FITC conjugated HR-crotamine was also applied to Jurkat cell to determinate its anti-
proliferative activity. The overlapping curves obtained from multiple experiments with 
conjugated and unconjugated HR-crotamine confirms the reproducibility of the assay 
and the very similar behavior of the unconjugated and conjugated HR-crotamine up to 1 
µM concentration. Based on this result, we are confident that FITC conjugated HR-
crotamine can be used to study the effects of HR-crotamine on the cells. [Fig.6 B] 
In each cell line, ten concentrations of HR-crotamine were tested and the cells 
death/growth inhibition index was calculated. The curve fitting was then used to 
generate an IC50 value for each cell line. To compare the IC50’s from multiple cell lines 
we generated the heat map based on a logarithm scale. [Fig.6 C] After comparison of 
each cell line, we concluded that Jurkat cells demonstrated the highest sensitivity to HR-




partial growth inhibition with an IC50 of greater than 25 µM. Mouse myoblast C2C12 
cells were less sensitive than Jurkat cells, (IC50 at 2.8 µM), while the human 
mesothelioma cells, REN cells, exhibited limited sensitivity (IC50 at 44 µM). Two 
human melanoma cell lines were relatively insensitive, the B16-F10 cell line exhibited 
slight growth inhibition with concentrations of the HR-crotamine >500 nM while the 
SK-Mel-28 exhibited no significant growth inhibition. The pancreatic cancer cell line 
MIA PaCa-2 demonstrated similar sensitivity to C2C12 cells with a calculated IC50 of 
1.79 µM. In conclusion IC50 concentrations for HR-crotamine between different cell 
lines varied greatly reflecting the notable selectivity of HR-crotamine’s growth 
inhibitory activity. 
Our results demonstrating the cell-selective activity in the cytotoxicity of HR-
crotamine parallels a report in the literature (Pereira et al., 2011) that also noted the very 
selective effects of C. durissus terrficus crotamine, on cancer cell cytotoxicity. The cell 
selective effects of myotoxins on cell proliferation argue against that this activity reflects 
a non-specific interaction of the positively charged toxin with the negatively charged cell 
membrane. Also, some cells with a very small surface-to-volume ratio, such as non-
adherent Jurkat cells are very sensitive whereas adherent cells, such as HeLa cell, 
HEK293T cell and REN cell, with much larger plasma membrane surface areas were 
relatively insensitive.  
There is a published report that attributes the selective cytotoxic effects of 
crotamine on cancer cells to their underlying proliferative rate (Nascimento et al., 2012). 




not support this hypothesis. The melanoma cell lines we tested have a doubling time of 
between 24 hr (B16-F10) and 35 hr (SK-Mel-28). In contrast, HEK293T cell has a 
doubling time of 20 hr. Jurkat cells have an 18 hr and C2C12 double every 20 hr. There 
is no correlation between the doubling times of the cells we have used in our screen and 
their relative sensitivity to the anti-proliferative activity of HR-crotamine.  We 
interpreted the results we have obtained as being compatible with our hypothesis that a 
specific target (or receptor) expressed on the surface of certain cancer cells, but not 
others, accounts for the selective effects of HR-crotamine on the proliferative activity of 
cancer cells.  
 
Time course of the cytotoxic effect of HR-crotamine on selected cancer cell lines 
We used some of the same cell lines tested in cell viability study to evaluate the 
time course for the cytotoxic activity of HR-crotamine. Specifically, we wanted to 
determine if the anti-proliferative activity observed in the cell viability study (as 
measured at 72 hr) reflected a very acute effect of the toxin (which might be compatible 
with an acute biophysical effect on membrane permeability, or whether it reflected a 
sustained effect on cellular function. To address this question the effect of HR-crotamine 
on cell growth was evaluated 24, 48 and 72 hr after the addition of the toxin to the cells. 
[Fig.7 A] The results we obtained demonstrated that differences in cell number in Jurkat 
cells was detectable at 24 hr and increased progressively thereafter, indicating a 
sustained anti-proliferative effect. Comparison of results obtained with Jurkat, REN and 




sustained anti-proliferative activity and not an acute effect. [Fig.7 B, C] To confirm this 
observation, we used a CellTiter-Blue® assay to measure the effect of HR-crotamine on 
the viability of multiple cell lines under multiple conditions. [Fig.7 D] The results 
obtained demonstrate that Jurkat cells were much more susceptible to the cytotoxic 
activity of HR-crotamine at both 24 hr and 72 hr than the other cell lines tested.   
 
Fig. 7. The growth inhibitory effect of HR-crotamine on Jurkat cell  
A) The time course for the effect of HR-crotamine (0.5 µM) on Jurkat cell proliferation. 
PBS serves as the negative control. The results shown are the mean+/-standard deviation 
for 4 replicates of cell number determinations at the times indicated. (** significance, 
P<0.05)  B) The time course for the effect of  HR-crotamine (0.5 µM) on HeLa cell 
proliferation Conditions the same as for Panel A  C) The time course for the effect of  
HR-crotamine(0.5 µM) on REN cell proliferation The conditions same as for Panel A .  
D) CellTiter-Blue assay for the effect of HR-crotamine on cancer cell proliferation Cells 
were treated by HR-crotamine with graded concentration (up to 1 µM) was cultured for 
72hr. CellTiter-Blue (CTB) activity was measured by 560/590 absorbance was 
monitored and the data normalized to the 0 hr values. The results shown are the mean+/-




Measurement of apoptosis vs necrosis 
To further characterize the effects of HR-crotamine on cell viability, we 
measured whether HR-crotamine induced apoptosis or necrosis in cancer cell lines. 
Apoptosis was detected using the CellEvent™ Caspase-3/7 assay using both fluorescent 
cell imaging and flow cytometry. The results obtained showed that there was no 
evidence for the induction of apoptosis as measured by Caspase-3/7 signal compared 
with Etoposide, the positive control, in both Jurkat and HeLa cells HR-crotamine does 
not induce measurable apoptosis in all of the test concentration, up to 1 µM [Fig. 8]. 
 
Fig. 8. Measurement of Apoptosis in HR-crotamine -treated Jurkat and HeLa cells 
Jurkat and HeLa cells were treated with graded concentrations of HR-crotamine or 




(Fig. 8. Continued) 
time point. The stained cells were then applied to the cell segmentation and count. The 
chart is curve fitted based on each data point. The data points are presented in the 
mean+/-standard deviation.   
 
Cytotoxicity kinetics 
To address the question of whether the growth inhibitory activity of HR-
crotamine was attributable to its potential membrane disrupting activity, we compared 
the kinetics of myotoxin-induced cytotoxicity with that of an established membrane 
peturbant such as SDS. Multiple cell lines were examined from 0.5 hr to 72 hr after the 
addition of multiple concentrations of SDS and HR-crotamine to the wells. A 
concentration of 0.0025% w/v of SDS induced 100% cell death in HEK293T, HeLa, SK-
Mel-28, C2C12 and Jurkat cells within 0.5 hr. In the higher concentration of SDS 
present, 0.02%, the cell apoptosis was trigger as expected. After 4 hr, the apoptotic 
population was reduced in total population may due to most cells were eliminated within 
4 hr. By contrast, in the HR-crotamine treated group, the apoptotic cells were very few at 
any time points. [Fig. 9] Based on the observation on SDS treated cells, the apoptosis 
was triggered immediately, once the cytoplasm membrane interrupted. However, the 
HR-crotamine, even in highest test concentration, was not increase the percentage of 
apoptotic population. The HR-crotamine may neither impair the cells membrane 





Fig. 9. The comparison for apoptotic population triggered by HR-crotamine or SDS 
on multiple cell lines. 
Several concentrations of SDS and HR-crotamine were applied to multiple cell lines and 
the percentage of apoptotic cell population in total population was monitored by 
DRAQ7TM staining and DAPI staining at 0.5 hr, 4 hr, 24 hr and 72 hr. Each data point 




Comparison of the effect of HR-crotamine on multiple leukemia cell lines  
Our initial studies characterized the effects of HR-crotamine of Jurkat cells, a 
CD3 positive, IL-2 expressing T-cell leukemia cell line isolated from 14-year-old boy. 
To examine the generality of the observed effects, we compared the activity of HR-
crotamine on Jurkat cells with its activity on 2 additional human T-cell leukemia cell 
lines, CCRF CEM and Molt-3 cell. All 3 cell lines showed inhibition of cell proliferation 
in response to HR-crotamine as measured by both cell counting and CellTiter-Glo assays 
but there were modest quantitative differences in the sensitivity of the different cell 
lines. [Fig.6 A] Molt-3 cells and Jurkat cells were comparable and CCRF CEM cells 
were less sensitive to the growth inhibitory effects of HR-crotamine. SK-MEL cells and 
HeLa cells were used as the reference for HR-crotamine insensitive cells. [Fig.10 A] 
These studies confirmed that the relative sensitivity of Jurkat cells to the growth 
inhibitory activity of HR-crotamine was not unique to Jurkat cells but was a general 
property of Human T-cell leukemia cells. 
Our hypothesis is that the differential sensitivity of cancer cell lines to cytotoxic 
activity of HR-crotamine, is based on the differential expression of specific molecular 
targets (or receptors) that mediate the cytotoxic effects. Based on previous studies 
carried out on the biological activities of snake venom myotoxins, we considered two 
specific classes of targets, Kv channels or HSPG’s, as the best candidates to account for 
the differential effects of HR-crotamine of cell proliferative activity. To test this 
hypothesis, we tested the level of expression of 4 major classes of Kv channels Kv1.1, 




on the three “sensitive” leukemia cell lines and HeLa cells, a “resistant” cell line. The 
results obtained from this study [Fig.10 B and C] showed that all 4 cell lines expressed 
comparable levels of Kv1.1, Kv1.2 and Kv1.5 but dramatically difference levels of 
Kv1.3 channel. The Kv1.3 channel transcript was detected in all of the T cell leukemia 
cell lines but was close to undetectable in HeLa cells. [Fig.10 B] The level of HSPG 
expression was comparable between the leukemia cells and HeLa, making it unlike that 
differential expression of these proteins accounted for the selective effects of HR-
crotamine on cell proliferation. Based on these results, we narrowed the test of our 
hypothesis to address the question of whether differential expression of Kv1.3 could 






Fig. 10. The relation between cell growth inhibition effect and the expression level 
of potential binding target.  
A) CellTiter-Glo assay for the effect of HR-crotamine on cancer cell proliferation Cells 
treated with graded concentrations of HR-crotamine were cultured for 72 hr. CellTiter- 
Glo activity was measured by luminescence plate reader. The results shown are the 
mean+/-standard deviation of the luminescence signal for 4 replicates of CellTiter-Glo 
test. B) Measurement of Kv1.1, Kv1.2, Kv1.3 and Kv1.5 channel expression in leukemia 
cell lines and HeLa cells Gene specific transcripts were quantitated by real-time qPCR 
with gene specific primers. GAPDH was used as internal reference. The results shown 





(Fig. 10. Continued) 
C) HSPG receptor level in leukemia cell lines and HeLa cells An ELISA assay was used 
to measure the level of HSPG’s in protein samples prepared from the total cell 
membrane preparation from each of the cell lines. Each bar is normalized to the level of 
HSPG in HeLa cells. The results shown are the mean+/-standard deviation for 3 
replicates of HSPG expression level determinations. 
 
Correlation of susceptibility versus putative targets 
Kv’s in sensitive versus resistant cells 
Transcript and protein expression patterns 
Since we have previously profiled the relative sensitivity of multiple cell lines to 
the growth inhibitory effects of HR-crotamine, we examined the level of endogenous Kv 
channel expression to determine if these was a relationship between the level of 
expression of a specific Kv channel and the sensitivity of that cell line to HR-crotamine. 
For these studies we focused on four Kv channels, Kv1.1, Kv1.2, Kv1.3 and Kv1.5, 
because previous patch-clamp studies had reported that the first three (Kv1.1, Kv1.2, 
Kv1.3) were sensitive to inhibition by snake venom myotoxin whereas Kv1.5 was not. 
(S. Peigneur et al., 2012). We used gene-specific real-time PCR to examine the 
expression level of the Kv channel transcripts in cDNA prepared from RNA from 
multiple HR-crotamine sensitive and insensitive cell lines. The real-time qPCR assay 
that we used was run in 20 µl volume master mix that included 10 µl FastStart SYBR 
Green Master (Roche, Inc., Switzerland), 1 µl of forward and reverse primer mix, 1 µl of 
cDNA sample and 8µl of molecular grade water. Each sample was run in triplicate. 
Beta-actin and GAPDH, two house-keeping genes were used to normalize the data from 




PCR Systems for 40 cycles. The protocol includes 95oC at 1 min and 55oC at 1 min 
followed by a melting curve step, for each cycle. The calculated final results were 
presented as the mean+/-standard deviation format. [Fig.11] The results of this study 
showed that there was absolutely no correlation between the level of expression of 
Kv1.1, Kv1.2 or Kv1.5 and the sensitivity of the cells to HR-crotamine’s cytotoxic 
activity. There was, however a highly significant negative correlation between the level 
of expression of Kv1.3 and the IC50, namely the higher the level of expression of the 
Kv1.3 transcript, the lower the IC50 for the growth inhibitory effect of HR-crotamine. 
 
Fig. 11. The Kv channel expression level and HR-crotamine sensitivity correlation 
analysis  
The IC50 value for the growth inhibitory effect of HR-crotamine for each of seven cancer 
cell lines was plotted against the relative level of Kv1.1, Kv1.2, Kv1.3 and Kv1.5 
transcript expression. Values are plotted on a logarithmic scale. Error bars indicates the 
standard deviation. The solid line in the chart for the Kv1.3 channel correlation 






Studies on the Overexpression of Kv Channels in cell lines. 
The next step in our studies was to determine whether overexpressing Kv1.3 in 
cells rendered them susceptible to the growth inhibitory activity of Kv1.3. To achieve 
this goal, we had to optimize the transfection conditions for cell survival and highest 
transfection rate.  
Kv channels are expressed at very low levels in most cells, making the study of 
the direct interactions of putative inhibitors with Kv channels technically difficult. In the 
case of a scorpion toxin that was thought to bind Kv channels, overexpression of the 
channels in a cell line with very low endogenous Kv channel expression was used 
successfully to demonstrate direct interactions (Gamper et al., 2002). To generate human 
Kv channel expression vectors, Kv1.1, Kv1.2, a N-terminal truncated version Kv1.3 that 
lacks sequences necessary for plasma membrane insertion (Kv1.3 truncate) and Kv1.5 
channel was first cloned from commercially available vectors. The full length Kv1.3 
channel was cloned from the total mRNA extracted from Jurkat cells. The pcDNA3 
mCherry LIC cloning vector(6B) was used to create the eukaryotic overexpress vector 
suitable for transfection into selected cell lines. This vector includes an mCherry 
fluorescent tag can be fused in-frame to the C-terminus of the recombinant protein. The 
inserted sequences were confirmed by both PCR fragment length determination and gene 







Fig. 12. Overexpression of the Kv channels in HeLa cells  
A) The confirmation of Kv channels insert segment size Kv1.1, Kv1.2, Kv1.3 full length, 
Kv1.3 truncate and Kv1.5 cDNA’s were cloned using gene specific primers and double 
digestion with restriction enzymes. The cDNA’s were ligated into the pcDNA3 mCherry 
LIC cloning vector(6B) with T4 ligase and the size of the insert sequences was 
confirmed by DNA gel analysis. The expected size for each DNA segment is listed at the 
bottom of the figure. B) Western blot of the HeLa cell with Kv channels overexpression 
The Western blot was applied to the total protein harvested from the HeLa cell with Kv 
channel overexpression. The rabbit anti-mCherry antibody was applied in 1:1000 
dilution while the mouse anti-Kv1.3 channel antibody was diluted in 1:500. The beta-
actin amount in each sample loading is also presented at lower panel to indicate the 
equal amount of protein sample was applied. The expected molecular weight is listed at 




To confirm that the expression vectors were generating the anticipated proteins in 
transfected HeLa cells, the presence of expressed proteins of the correct size was 
confirmed by Western blot. Total cell proteins harvested from HeLa cells transfected 
with the individual Kv channel expression vectors, were fractionated by SDS-PAGE and 
the transfected fusion proteins detected using anti-mCherry antibodies. In the case of 
Kv1.3 the fusion protein was also detected with an anti-Kv1.3 channel antibody as well. 
Western blot analysis confirmed the expression of each of the Kv channel proteins with 
the anticipated correct size. [Fig.12 B]  
The final goal of this overexpression model was to determine whether the 
overexpression of Kv channels impacted the viability of the transfected cells and their 
sensitivity to growth inhibition by HR-crotamine. The viability of HeLa cells transiently 
transfected with each of the Kv channel expression constructs (or empty vector as a 
control) was evaluated after 72 hr treatment with 1 µM of HR-crotamine or negative 
control (PBS). The results we obtained indicated no significant differences in cell growth 
were observed (data not shown). There are obviously many possible interpretations to 
this negative result. It could be due to the limited level of expression of Kv1.3 in the 
transfected HeLa cells (or the limited fraction of cells expressing adequate levels of 
Kv1.3 channel on the cell surface). Alternatively, multiple counter-regulatory 
mechanisms may have suppressed the level of expression of the channel, or its 
downstream effectors such as Ca+2 regulatory systems, in response to the overexpression 




regulatory activity in HeLa cells or other ion channels may function to compensate for 
artificially induced changes in Kv1.3 channel expression,   
 
HSPG depletion studies 
Our preliminary correlative studies had pointed away from a relationship 
between the level of expression of HSPGs on multiple cancer cell lines and their 
sensitivity to the growth inhibitory activity of HR-crotamine. The quantitative results of 
ELISA were summarized in the bar chart. [Fig.13 A] The levels of HSPG on the surface 
of C2C12 cell, HeLa cell and SK-Mel-28 cell are very close. Jurkat cells had lower 
levels of HSPG’s than the other cells lines. To ensure that the level of HSPG’s on the 
surface of cells was not a contributor to the sensitivity of the cells to the growth 
inhibitory activity of HR-crotamine, we next carried out depletion studies using 
heparinase III to reduce the levels of HSPG’s on both myotoxin sensitive and insensitive 
cell lines. Cells treated with buffer alone served as a negative control while digestion 
with Trypsin/EDTA served as a positive control. As shown in Fig. 13 A, treatment with 
heparinase III resulted in a major decrease in HSPGs (as measured by ELISA using 
mouse anti-HSPG/Heparin) on the surface of all three cell lines tested. The next step was 
to determine whether the reduction in HSPG content on the surface of the cells reduced 
their sensitivity to growth inhibition by HR-crotamine. [Fig.13 B] The results obtained 
showed clearly that HR-crotamine was effective in reducing the proliferative activity in 
heparinase III-treated Jurkat cells. There were minimal effects on HR-responsiveness in 




that while HSPG’s may bond to myotoxins, this effect is not essential for the growth 
inhibitory activity of the myotoxin. 
 
 
Fig. 13. Heparinase III digestion of HSPG’s and the effect of HSPG depletion on HR-
crotamine’s antiproliferative activity 
A) Measurement of cell surface HSPG levels in Heparinase III-treated cells. C2C12, 
HeLa, SK-Mel-28 and Jurkat cells were treated with Heparinase III and the levels of 
HSPG’s in the cell membrane prep were determined by first lysing the cells in a 
detergent cocktail, sediment the cell membranes and solubilizing membrane proteins was 
in 0.5% Triton-X100. Both solubilized membrane proteins and the pellets were analyzed 
using an indirect ELISA with mouse anti-HSPG/Heparin in 1:2000 dilution. All 
determinations were in triplicate and the values represent the mean+/-standard deviation. 
The PBS group represent the baseline HSPG levels in each of the cell lines. The trypsin- 
treated group represents the maximal reduction of cell surface HSPG’s achievable by 




(Fig. 13. Continued) 
crotamine treated cells. Jurkat and two skin melanoma cell lines, B16-F10 and SK-Mel-
28, were treated with 7 unit/ml Heparinase III for 3 hr and then washed with PBS. The 
cells were then continued to be cultured with Heparinase III present with or without the 
addition of HR-crotamine (1 µM). Etoposide (0.1 mM) served as the positive control and 
PBS as the negative control. The result indicate that the Heparinase III has a small effect 
on cells proliferation but significant growth inhibition was observed in the cells treated 
with both Heparinase III and HR-crotamine. For all three cell lines, the Heparinase III-
treated cells are more sensitive than the Heparinase III- untreated cells. 
 
In summary, the preceding studies have suggested that the cytotoxic activity of 
HR-crotamine are not readily explained by the potential interactions of the myotoxin  
with the cell’s lipid bilayer membrane nor with cell surface HSPG’s (Nascimento et al., 
2007). The results we have obtained point to the anti-proliferative activity of the 
myotoxin are most likely due to interactions with one or more targets (i.e. receptors) on 
the cell surface that are responsible for the transfer of the anti-proliferative activity to the 
interior of the cell.  
 
Discussion 
Implications for selectivity 
Malignant versus normal cells 
The basic question we have been addressing is why certain cancer cells and 
cancer cell lines are more sensitive than others or normal cells to the cytotoxic activity 
snake venom myotoxins. Although a number of different explanations, such as 
differences in doubling time or metabolic activity, interactions with membrane lipid 




channels, have been advanced to account for this selective activity, none has been 
definitively demonstrated to account for the anti-proliferative activity of this class of 
toxins. The preliminary studies we have carried out with sensitive versus insensitive 
cancer cell lines have eliminated most of the potential mechanisms proposed by others. 
Our results have pointed towards a specific interaction with one or more classes of 
membrane receptors as serving as the most likely mechanism for the action of these 
proteins.   
 
The Jurkat cell model for HR-crotamine study 
In an initial survey of myotoxin sensitive versus insensitive cell lines suggested 
that Jurkat cells would make a useful model system for a sensitive cell line and HeLa 
cells were a good example of an insensitive cell line. The Jurkat cells were not unique, in 
their sensitivity to HR-crotamine, several other human T-cell leukemia cell lines 
exhibited comparable sensitivity. Similarly, the insensitive properties of HeLa cells were 
shared with other cell lines including melanoma and epithelioma cell lines. Jurkat cells 
were readily transfect-able and were convenient for long term culture studies and had a 
relatively short doubling time. These properties were important for future studies which 
would require specialized analysis such as the measurement of cell surface binding 







Proposed mechanism based on observations 
No correlation between HSPG expression level and sensitivity of cells to HR-
crotamine  
The human T-cell leukemia cell lines, Jurkat, CCRF-CEM and Molt-3, are small 
spherical cells that grow in suspension, with relatively low cell surface area/volume ratio 
and large nuclear/cytoplasmic volumes compared with other attached malignant cell 
lines. We have found that these cell lines were the most sensitive to HR-crotamine 
among the cell lines tested. Some groups have proposed that the cytotoxic activity of 
myotoxins such as HR-crotamine are dependent on their internalization in a receptor-
mediated, energy required process. They have suggested that the principal receptors for 
this process could be syndecan-3 and its heparan side chain(Nascimento et al., 2007). In 
our studies, we found no evidence for HR-crotamine internalization and no relationship 
between HSPG expression or levels and the growth inhibitory activity of the myotoxin. 
 
Kinetics: Receptor-mediated versus biophysical effect 
Some studies from other groups have suggested that the cytotoxic activity of 
myotoxins may be due to its cell penetrating due to the high positive charge of the 
molecule at physiological pH and its potential ability to interfere with the cell 
membrane's lipid bilayer structure. The presence of a large amphipathic surface on the 
crotamine molecule is hypothesized to permit its breaching of the lipid bilayer structure 
subsequent disruption of the membrane structure. We do not believe this type of 




between the lipid bilayers and the detergent/or detergent-like molecules are very rapid 
and generally very complete (Schilling, Kamholz, & Yager, 2002). We demonstrated the 
kinetics of this type of effect in studies that compared the cytotoxic activity of a 
membrane-disrupting detergent such as SDS with HR-crotamine. Even very low 
concentrations of the detergent have effects on cell viability that are readily detected 
within 30min. HR-crotamine on the other hand requires many hours of exposure to 
decrease the proliferative activity of sensitive cells. These studies make it very likely 
that the myotoxin exerts its anti-proliferative activity not via a detergent-like biophysical 
disruption of cell membrane bilayer structures. 
According to the previous study, the toxins may achieve toxic effects by 
plugging into ion channel pores and occlude it (Yount et al., 2009). Thus, the ability of 
structurally divergent toxins to interact with a particular Kv channel relies on a certain 
spatial distribution of amino acid residues that are keys to the toxin-channel interaction. 
Based on their structure, these toxins were classified into three groups: 1) myotoxins of 
the crotamine type, which is considered as voltage channel modulators; 2) "three 
fingers" toxins; and 3) substances homologous to protease inhibitors and Kv1 channels 
blockers (Kordis & Gubensek, 2000). Most of these toxins are 23-64 residues in length 
and are tightly packed by three or four disulfide bridges. They can modify potassium 
permeability in excitable and non-excitable cells at nanomolar concentration level or 
below(Soares et al., 2000).  
The particularly high binding affinities of channels, such as Kv1.3 channel, to 




that carry charges of between +5e and +8e are drawn toward the negatively charged 
receptor site, near the entrance of the selectivity filter, where they physically occlude the 
conducting pathway of K+ ions based on the molecule shape (Swartz & MacKinnon, 
1997). The crotamine contains a large number of cationic residues and have a +7.6e at 
pH. 7.4 (I. Kerkis et al., 2010). Thus, in human normal blood pH. range, the crotamine 
have all of the prerequisite property to bind to the channels. Based upon the analysis of 
the sequences, it suggests that the toxins may bind to channel may via two basic charge 
residues, lysine and arginine. Due to the unique distribution of the charge in myotoxin 
molecule, several H-bonds are formed between the toxin and channel to stabilize the 
binding after the initial binding(Ward, Chioato, de Oliveira, Ruller, & Sa, 2002).   
 
Type of cytotoxic activity (proliferation inhibition versus necrosis versus apoptosis) 
We used a variety of experimental techniques to demonstrate that, under the 
conditions used to show significant decreases in cell proliferation, that HR-crotamine 
does not induce either cell necrosis or cell apoptosis. Even after 72 hr of incubation with 
1µM HR-crotamine and in the presence of major growth inhibition, no significant 
increase in the number of dead or apoptotic cells was detected. Our data suggests that 
under our conditions HR-crotamine can have a purely anti-proliferative effect on 




CHAPTER II  
IDENTIFICATION OF THE CELL SURFACE TARGET THAT MEDIATES THE 
ANTI-PROLIFERATIVE ACTIVITY OF HELLERIED CROTAMINE 
 
Introduction 
The identification of the cell surface protein that is the target  for HR-crotamine 
binding is the critical first step in establishing the molecular mechanisms involved in the 
anti-proliferative activity of the myotoxin (Campelo et al., 2016). In our previous studies 
we have identified, HR-crotamine sensitive and insensitive cells and have provided 
evidence in support of the hypothesis that cell surface Kv receptors are candidates for 
mediating the cytotoxic activity of HR-crotamine (S. Peigneur et al., 2012). To test the 
hypothesis that a subset of Kv channels serve as the functional targets of HR-crotamine 
target, we have employed a set of molecular and pharmacologic approaches to 
characterize HR-crotamine binding on sensitive and insensitive cell lines. 
 
Methods 
Cell Surface Binding Assay 
We used two binding assay protocols, direct binding using varying 
concentrations of FITC HR-crotamine and a competitive binding assay using a fixed 
concentration of FITC HR-crotamine and varying concentrations of unlabeled HR-
crotamine, to measure the binding of HR-crotamine to intact Jurkat cells. The FITC 




labeling kits (Thermo Fisher Scientific, MA) follow the vendor’s recommended 
protocol. In the direct binding assay, 1X106 Jurkat cells were incubated with graded 
concentrations (9 µM-100 nM, in half fold dilution) of FITC labeled HR-crotamine 20 
min on ice to limit endocytosis. The cells were then washed with ice-cold PBST buffer 
(0.5% v/v Tween-20) to reduce non-specific background binding The PBS without FITC 
HR-crotamine served as the negative control. The cells were then analyzed for bound 
FITC HR-crotamine with a LSRII flow cytometer. The results were normalized within 
the signal window between the positive and negative controls to reduce the interference 
from the background and non-specific binding. 
In the competitive binding assay, graded concentrations (from 0 µM to 20 µM, 
in) of unlabeled HR-crotamine (from 20 µM-0 µM, in half fold dilution) was mixed with 
1 µM of FITC labeled HR-crotamine before addition to 1X106 Jurkat cells, the cells and 
the pre-mixed HR-crotamine were incubated on ice for 20min as described above. The 
PBS buffer served as the negative control and FITC HR-crotamine alone served as the 
positive control to generate the signal window boundaries. After incubation, cells were 
washed, processed by fluorescent flow cytometry and the data analyzed as described for 
the direct binding assay. 
 
Overexpression of Kv channels and binding study 
The pCIG3 (pCMV-IRES-GFP version 3) lentiviral expression vector (from Add 
gene, MA) [Fig.14 A] was used to construct Kv channel expression vectors (Kv1.1, 




recombinant channel cDNA is fused, in frame, to a Flag tag. This expression vector 
system also has ERIS-GFP to facilitate positive clone selection. The gene-specific 
primers used to characterize the inserts are listed in Table 4. HEK293T were transfected 
with the expression vector constructs, psPAX2 and pMD2G vector using 
Lipofectamine® 3000 reagent (Thermo Fisher Scientific, MO) following the vendor’s 
recommended protocol. After 48 hr, the culture medium was harvested to collect the 
lentivirus, and the lentivirus was used to transfect Jurkat cell using a protocol in which 
400 µl of lentivirus media and the Jurkat cells were mixed and centrifuged at 2000 rpm 
for 120 min to increase the transfection efficiency. The transfected Jurkat cells was 
ready for FACS sorting after 48 hr of cell culture. [Fig.14 B] 
The overexpression of each Kv channel in Jurkat cells was tested and confirmed 
by Western blot (with mouse anti-Flag antibody,1:2000) and cell surface staining of non-
permeabilized cells with anti-Flag antibodies. In the surface staining experiments, cells 
were stained with (1:1000) mouse anti-Flag antibody following a conventional surface 
staining protocol. Both the stained cells and Western blot membranes were treated with 
1:5000 anti-mouse secondary antibody. The Western blot result was visualized by ECL 
buffer (Thermo Fisher Scientific, MO). Immunofluorescent images were collected using 








Table 4. Gene specific primers used to amplify the Kv channel sequences prior to 





Fig. 14. The lentiviral expression vector system used to manipulate (overexpression 
and knockdown) of Kv channels in Jurkat cells.  
A) The gene map of the lentiviral expression vector (pCIG3) that was used for the 
expression of Kv channels in the Jurkat cells. The vector contains the ampicillin 






(Fig. 14. Continued) 
B) The protocol used for the overexpression and knock down of Kv channels in Jurkat 
cells. Individual Kv channels were amplified from Jurkat cell cDNA’s and cloned into 
the pCIG3 expression vector) or the knockdown vector (Tet-pLKO-puro). Lentivirus 
constructs were applied to Jurkat cell. Positive clones were selected by GFP sorting or 
puromycin selection. The level of overexpression and the efficiency of knock down was 
tested by gene specific real-time qPCR, cell membrane protein ELISA or indirect 






(Fig. 14. Continued) 
C) The gene map for the Tet-pLKO-puro vector This vector was used to generate 
shRNA’s, which were used to knock down Kv channel transcripts in Jurkat cells. The 
vector includes a doxycycline-inducible expression system and a puromycin resistance 
gene for clonal selection. 
 
To measure the binding of HR-crotamine to cells, 1 µM of FITC-conjugated HR-
crotamine was applied to pre-chilled Jurkat cells (native cells as well as cells transfected 
with either lentiviral expression vectors for each of the Kv channel constructs or Tet-
pLKO-puro shRNA expression constructs for Kv channels knockdown studies) for 30 
min, on ice. The control for these experiments were Jurkat cells transfected with the 
empty pCIG3 vector (or Tet-pLKO-puro vector with scramble shRNA). After a wash 
step, cells were fixed and analyzed by flow cytometer. The mean of each cell 





Western blot for Kv channel overexpression  
Both membrane proteins and cell cytoplasm preparations (80 µg/lane) were 
fractionated by SDS-PAGE and transferred to membranes using standard protocols. 
Membranes were probed with anti-Flag anti-body (1:2000) and secondary antibody (1: 
5000). Bound antibodies were detected with ECL substrate plus reagent (Thermo 
Scientific, MA). 
 
Immunostaining of Kv channels 
Transfected cells grown on glass coverslips coated with poly-D-lysine were fixed 
by 4% PFA buffer and blocked with 5% BSA or non-fat milk followed by washing twice 
in PBS. The cells were then stained with primary antibody (1:2000) in TBS buffer with 
5% BSA for 2 hr on ice. Secondary antibody was applied in a 1:2000 dilution in TBST 
buffer for 2 hr on ice. The cells were mounted using slow-fade buffer and analyzed using 
a DeltaVision Elite deconvolution microscopy system. 
 
Membrane protein isolation 
Cell membrane and the cytoplasmic protein preparations were generated using 
the Mem-PER Plus membrane protein extraction kit (Thermo Fisher Scientific, MA) 
following the vendor’s recommended protocol. Briefly, cells were harvested by washing 
them from the culture plate by flushing with PBS addition of proteinase to avoid cell 
membrane protein degradation. All reagents were pre-chilled to minimize protein 




permeabilized by mixing with 0.75 ml of permeabilization buffer. After 15min 
incubation at 4oC, the cytoplasmic protein fraction was generated by centrifugation for 
15min at 16,000 x g with collection of the supernatant. The cell pellet was mixed with 
0.5 ml solubilization buffer to extract the membrane proteins. [Fig.3 A] After 30 min 
incubation at 4oC, the membrane protein was separated from the insoluble fraction by 
centrifugation for 15min at 16,000 x g. The membrane and cytoplasm proteins were 
fractionated by SDS-PAGE and probed for specific proteins by Western blot analysis. 
 
Biotinylation of HR-crotamine  
To bind HR-crotamine to Dynabeads M-280 streptavidin beads, HR-crotamine 
was biotinylated using the EZ-Link Sulfo-NHS-Biotin kit. The amounts of the HR-
crotamine and Sulfo-NHC-LC-Biotin was calculated for an optimal reaction ratio and 
the mixture of 10 mM Sulfo-NHS-LC-Biotin and HR-crotamine was incubated on ice 
for 2 hr. Excess biotin reagent was removed by a desalting column and the biotinylated 
HR-crotamine was recovered and confirmed by the HABA assay.  
 
Pull down analysis of HR-Crotamine Binding proteins 
Pull-down analysis was performed with Dynabeads M-280 streptavidin beads; 
biotinylated HR-crotamine and the cell protein preparations (cell membrane or 
cytoplasm protein fractions). The Dynabeads M-280 beads were washed 3 times and 
then incubated with 15 µM of biotinylated HR-crotamine at 4oC for 3 hr. The beads with 




background. The blocked beads were washed 3 times with PBS to remove unbound HR-
crotamine and BSA. Membrane proteins from Jurkat cells expressing Flag tag-fused Kv 
channels were incubated with the beads at 4oC overnight with Dynabeads M-280 without 
bound HR-crotamine serving as the background control. The beads with pull-down 
proteins were washed with PBS buffer for three times (15 min each) and prepared for 
SDS-PAGE, followed by silver staining and Western blot analysis.    
 
Knockdown of Kv Channel in HR-crotamine sensitive cell lines 
Knockdown of Kv1.3 and Kv1.5 channels were performed using an RNA 
interference silencing system. The shRNA sequences that target to each Kv channel were 
designed to achieve the best knockdown efficient. For each gene, two shRNA sequences 
were designed and tested. The gene-specific shRNA was obtained from IDT DNA 
synthesis facility and the backbone of the transfection vector is Tet-pLKO-puro. The 
gene-specific shRNA’s designed as described in Table 5 and the primers were annealed 
using a gradual temperature reduction protocol. Specifically, 250 µg of each strand 
primer was added to a 50 µl reaction system that was heated to 95oC and then cooled 
with a temperature decrement rate of 1oC per 10 min, until the reaction reached room 
temperature. The processed shRNA sequence and plain vector was digested with AgeI 
and EcoRI. [Fig.14 C] After the gel purification step, the annealed insert sequence and 
the cleaved vector was ligated by T-4 ligase at the vendor recommend condition (16oC, 
overnight). Due to utilize the isocaudomers’ sequence for the adaptor, the ligation was 




transferred into One Shot® Stbl3™ Chemically Competent Cells. The positive clone 
was selected by ampicillin selection pressure, and the positive colony was picked for 
expansion. The purified plasmid from an expanded single clone was sequenced in order 
to confirm the correct clone.  
HEK293T were transfected using a lentivirus system that included the Tet-
pLKO-puro vector containing the gene-specific shRNA sequences and psPAX2 and 
pMD2G vectors. The lentivirus was generated in HEK293T cells serving as the host cell 
for lentiviral assembly. Briefly, the HEK293T cell was seeded in 6-well plate and the 
cell was transfected with constructed 3 µg of Tet-pLKO-puro, 1.5 µg of pSPAX2 and 
1µg of pMD2G vector. The cell was transfected with lipofectamine 3000 at the 70-80% 
confluence. The cells were cultured for 48 hr until the supernatant culture media 
collected for Jurkat cell transfection. 
For lentivirus transfection, 1.5X105 Jurkat cells were cultured in FBS-free media 
for 2 hr and then mixed with the lentivirus – containing media (0.8ml of virus content 
media+0.8 ml of RPMI1640 complete medium) followed by centrifugation at 2000 rpm 
for 2hr. After an additional 6 hr of incubation, the transfected Jurkat cells were placed 
into complete RPMI-1640 media and incubated for 24 hr to allow for resistance gene 
expression prior to the addition of 2 µg/ml of puromycin for 3 weeks of positive clonal 
selection. Knockdown activity was induced by the addition of 1 µM of doxycycline and 
the efficiency of knockdown was determined via gene-specific qPCR.  
The real-time qPCR test was applied to the Jurkat cell that transfected with 




from cell samples using E.Z.N.A.® Total RNA kit (Omega Bio-tek, GA). The quantity 
and purity were measured by Nanodrop 2000 spectrophotometer (Thermo Fisher 
Scientific, MA).  Total mRNA was converted to cDNA using SuperScript III first-strand 
synthesis system following vendor’s instructions (Thermo Fisher Scientific, MA). The 
transcription level of Kv channels was determined by quantitative real-time qPCR by 
using FastStart Universal SYBR Green Master (Roche, Switzerland). The primers for the 
real-time qPCR was specifically designed for Kv channels (Kv1.1, Kv1.2, Kv1.3 and 
Kv1.5, detail in table 2) and two standard internal references primers (GADPH and beta-
actin) was used. The program for qPCR reaction followed the conventional protocol with 
annealing temperature at 50oC and all the reactions were carried out in triplicates format 
to achieve the improved reliability. 
The knockdown efficient was also confirmed by the ELISA of the level of the Kv 
channels in a total cell membrane protein using both mouse anti-Kv1.3 channel and 
mouse anti-Kv1.5 channel antibodies (Alomone Lab, Israel) and a standard indirect 











Table 5. The shRNA sequences used to knock down each Kv channels in Jurkat cell  
 
 
The cell viability assay used in the Kv channel knockdown and inhibitor studies 
was the same as the cell viability assay described in Chapter I, with the modification that 







Binding target cross-blocking assay 
In the cross-blocking assay, the cell binding protocol used was same as the 
competitive binding assay described previously except that graded concentrations of a 
chemical channel blocker, 0-20 µM CP-339818 (Sigma-Aldrich, MO) was added to the 
incubation mix to compete with 1 µM FITC-conjugated HR-crotamine binding prior to   
incubation with 1X106 Jurkat cells on ice for 20min. The cells were then analyzed for 
bound FITC HR-crotamine with a LSRII flow cytometry system using the same protocol 
used for the competitive binding assay. 
 
Result 
Binding of HR-Crotamine to Jurkat cells  
The first step in our search for the HR-crotamine target was to determine whether 
or not there was a saturable binding site for the myotoxin on the surface on intact HR-
crotamine-sensitive cells such as Jurkat cells. A cell surface binding assay was 
performed using graded concentrations (300 nM, 1 µM, 3 µM and 9 µM) of FITC 
labeled HR-crotamine: incubated with intact Jurkat cells for 20 min on ice and cell-
bound FITC -HR-crotamine detection using flow cytometry (for experimental details see 
Methods e. Cell Surface Binding Assay). The results of this ligand binding assay showed 
a single component binding curve at approached saturation at >2 µM and exhibited an 
EC50 of 1.3 µM. [Fig.15 B] The lack of complete saturation at higher concentrations is 
likely due to a modest contribution of non-specific (i.e. non-saturable) binding activity. 




florescence excluded from the nuclear and intracellular compartments and fully 
compatible with a specific cell surface binding activity. [Fig. 15 A] 
 
 
Fig. 15. Binding of FITC-labelled HR-crotamine to intact Jurkat cells.  
A) Direct visualization of FITC HR-crotamine bound to intact Jurkat cells Cells were 
stained with FITC conjugated HR-crotamine for 20 min on ice. Images were collected 
using a 40X objective and epifluorescence microscopy. DAPI staining was used to mark 
the cell nucleus. B) Direct binding assay for FITC-HR-crotamine binding to intact 
Jurkat using the Cell Surface Binding Assay as described in Methods using a fixed 
concentration of FITC-HR-crotamine and graded concentrations of unlabeled HR-
crotamine. The total binding data curve (red) and BC50 were calculated from the total 
concentration of FITC-labelled and unlabeled HR-crotamine in the binding assay. The 
dilution curve (green) is the amount of FITC-HR-crotamine bound to the cells in the 
presence of increasing concentrations of unlabeled HR-crotamine. The result is the 
mean+/-standard deviation of triplicate determinations. 
 
To confirm the results obtained with the direct binding assay and to ensure that 




crotamine as opposed to unlabeled HR-crotamine, we carried out a competitive binding 
using a fixed concentration of FITC-conjugated HR-crotamine (1 µM) and increasing 
concentrations of unlabeled HR-crotamine. [Fig. 15 C] The results obtained indicated a 
robust dilution in the binding of FITC-HR-crotamine by unlabeled HR-crotamine (Green 
line Fig. 15 C) confirming the presence of a saturable and compete-able binding site on 
the surface of Jurkat cells. The total binding curve (red line Fig. 15 C) was comparable 
to the direct binding assay as the BC50 1.34 µM was essentially the same as the BC50 
obtained with the direct binding assay, confirming that the binding constant reflected the 
binding of HR-crotamine to the cell.   
 
The Kv channel overexpression and localization was confirmed  
To test our hypothesis that the target for HR-crotamine binding to Jurkat cells are 
members of the Kv channel family, we first tested whether HR-crotamine binds to Kv 
channels by overexpressing Kv channels in Jurkat cells and then testing whether the 
overexpression of individual channels leads to increased HR-crotamine binding. The 
first step in this study was to demonstrate the ability to overexpress Kv channels in 
Jurkat cells. Due to the fact that endogenous Kv channels are expressed at low 
abundance in the Jurkat cells, we found it was necessary to overexpress the Kv channels 
in the cells to demonstrate their myotoxin binding activity. 
We constructed a series of recombinant pCIG3 (pCMV-IRES-GFP version 3) 
lentiviral vectors that included full length inserts for Kv1.1, 1.2, 1.3 and 1.5 and a 




including a C-terminal Flag tag (for details see Methods a. Overexpression of Kv 
Channels). We transfected Jurkat cells with each of these lentiviral expression vectors 
and then identified the expressed of Kv proteins by Western blot analysis of whole cell 
lysates using an anti-Flag antibody. [Fig. 16 A] Each of the transfected cells expressed a 
flag fusion protein with a size that was appropriate for the Kv channel-Flag fusion 
protein. The Kv1.1, truncated Kv1.3 and Kv1.5 transfected cells exhibited two to three 
additional, lower molecular weight bands that are likely due to proteolytic degradation of 
transfected Kv channels.  
Immunofluorescence analysis of Jurkat cells transfected with the Kv channel 
expression constructs showed clear expression of full length Kv1.1, 1.2, 1.3 and 1.5 both 
in the cytoplasm and at the cell periphery, indicating expression and insertion of the 
channel proteins into the Jurkat cell membrane. [Fig. 16 B, C] In contrast, cells 
transfected with the truncated Kv1.3 construct (which lacks the membrane insertion 
sequence) showed only diffuse cytoplasmic expression of the transfected protein. We 
also noted that over-expression of the full-length Kv1.3 channel but not the truncated 
Kv1.3 channel protein resulted in a noticeably more roundish shape to the transfected 
cells. Similar shape changes, but to a lesser degree were noted in cells transfected with 





Fig. 16. Kv channel overexpression in Jurkat cells 
A) Western Blot analysis Kv channel overexpression. Jurkat cells were transfected with 
lentivirus expression system containing inserts for Kv1.1, Kv1.2, full-length and a 
truncated Kv1.3 and Kv1.5 constructs each with a fused Flag tag. Cell lysates were 
fractionated by SDS-PAGE, transferred to PDF membranes and probed with anti-Flag 
antibody using a protocol described in Methods b. for Kv Channel Overexpression 
Western Blot B) Full length and truncated Kv1.3 channel inserts. The difference 
between the full length Kv1.3 and the truncated Kv1.3 constructs is the deletion of 52 
amino acids (shaded part) at the N-terminal that abolishes plasma membrane insertion 
activity C) Immunofluorescence detection of Kv channel fusion proteins in Lentivirus 
transfected Jurkat cell. Jurkat cells grown on poly-lysine coated cover slips were 
transfected with lentivirus expression vectors containing Kv channel constructs fused to 
a Flag tag. After 48 hr, cells were fixed, permeabilized and stained with anti-Flag 
primary antibody and fluorescent second antibody under conditions described in detail in 
Methods c. Immunostaining of Kv channels. Cell nuclei were stained with DAPI. Images 




Effect of Kv channel overexpression on HR-Crotamine binding 
With the ability to overexpress Kv channels on Jurkat cell, we were now in a 
position to determine if overexpression of specific Kv channels impacted HR-crotamine 
binding. The HR-crotamine binding activity of Jurkat cells overexpressing full length 
Kv1.1, Kv1.2, Kv1.3 and Kv1.5 were compared with the cell surface binding activity of 
non-transfected cells and cells transfected with an empty vector. [Fig.17 A] Expression 
of either Kv1.1, Kv1.2 and Kv1.3 on the surface of Jurkat cells significantly (P<0.05) 
increased HR-crotamine binding. Expression of Kv1.5 had no effect on myotoxin 
binding. To determine whether expression on the cell surface was essential for HR-
crotamine binding, we compared the binding activity of Jurkat cells overexpressing full 
length Kv1.3 with cells expressing a truncated version of the channel protein that was 
restricted to the cytoplasm. The results of this experiment showed clearly that expression 





Fig. 17. Effect of Kv channel overexpression on HR-crotamine Binding 
A) Effect of Full Length Kv channel overexpression on HR-crotamine binding Jurkat 
cell FITC-labeled HR-crotamine (1 µM) was incubated with Jurkat cell overexpressing 
specific full-length Kv Channels and the level of cell bound FITC-conjugated HR-
crotamine determined as described previous. Non-transfected Jurkat cells (WT) and 
Jurkat cells transfected with empty lentiviral vector (Empty Vector) served as the 
controls. The results are the mean+/-standard deviation of triplicate determinations. 
Statistical significance was determined by Student’s T-test and the (**) indicates P<0.05.  
B) Comparison of full length versus truncated Kv1.3 expression on HR-crotamine 
Binding. FITC-labeled HR-crotamine (1 µM) was incubated with Jurkat cell 
overexpressing either full-length or NH2-terminal truncated Kv1.3, in Fig. 16 B, and the 
level of cell bound FITC-conjugated HR-crotamine determined as described previous. 
Jurkat cells transfected with empty lentiviral vector (Empty Vector) served as the 
controls. The results are the mean +/-standard deviation of triplicate determinations. 






Pull down analysis and Co-immunoprecipitation (co-IP) 
 As an independent test of the interaction of HR-crotamine with KV channel 
proteins we performed a pull-down analysis using beads coated with HR-crotamine and 
membrane proteins purified from cells overexpressing the Kv channel proteins. The 
results of these experiments confirmed that HR-crotamine can bind to KV1.1, 1.2 and 
1.3 expressed in the membranes of Jurkat cells. [Fig. 18]  
 
Fig. 18. Pull-down analysis of the binding of HR-crotamine to membrane associated 
Kv 1.1, 1.2 and 1.3.  
The Jurkat cell was transfected with Kv channel overexpression vector (pCIG3 vector). 
The cell membrane protein was prepared by the Membrane Prep kit. Total cell 
membrane proteins prepared from Jurkat cells transfected with lentiviral vectors 
expressing Flag-tagged Kv1.1, Kv1.2 and Kv1.3 were incubated streptavidin Dynabeads 
coated with biotinylated HR-crotamine (see Methods g. Pull-down analysis of HR-
crotamine binding proteins). After washing proteins bound to the beads were solubilized, 
fractionated by SDS-PAGE and probed by Western Blot with anti-Flag antibody. 
Dynabeads with no immobilized HR-crotamine served as the control. The size of the 
Flag-tag fused Kv channel is: Kv1.1, 58 kDa; Kv1.2, 42kDa and Kv1.3, 65 kDa. B/HR-
crotamine: biotinylated HR-crotamine. 
 
Knockdown of the Kv channels in Jurkat cell 
The preceding studies used the overexpression of Kv channels in Jurkat cells to 




when the channel proteins were expressed on the surface of Jurkat cells. They did not 
however address the question of whether HR-crotamine bound to the endogenous Kv 
channels expressed on the surface of these cells. To address this question, we first 
developed inducible lentiviral shRNA expression constructs for each of the four Kv 
channels of interest (Kv1.1, 1.2, 1.3 and 1.5) and established experimental conditions 
under which induction of the shRNA’s led to a profound suppression (60-80% 
suppression) of Kv channel expression [Fig. 19 A] as measured by real-time qPCR. We 
then used these conditions to examine the effect of the knock-down of each channel on 
HR-crotamine binding activity. The results of this experiment [Fig. 19 B] showed that 
suppression of Kv1.1, 1.2 and 1.3 expression resulted in a significant decrease in HR-
crotamine binding in Jurkat cells whereas suppression of Kv1.5 had no effect. The 
suppression of each individual channel protein resulted in a fractional decrease in HR-
crotamine binding. Suppression of Kv1.1 expression resulted in a 20% reduction in 
myotoxin binding, suppression of Kv1.2 reduced binding by 25% and Kv1.3 by 30%. 
When combined the suppression of Kv channels, the expression appears to account for a 
minimum for 75% of the specific binding of HR-crotamine to intact Jurkat cells. This is 
a minimal estimate because the quantitative analysis of the Kv channel transcripts 
indicates that the suppression of expression of each transcript ranged from 60-80%. [Fig. 
19 A] These results provide strong evidence that Kv channels serve as the major target 






Cross competitive binding test with Kv1.3 blocker 
As an independent test for the hypothesis that Kv channels serve as a target for 
HR-crotamine binding to Jurkat cells, we investigated the ability of a well-characterized 
Kv 1.3 channel inhibitor, CP-339818 (Jimenez-Perez et al., 2016; Wulff, Castle, & 
Pardo, 2009) to interfere with HR-crotamine binding to endogenous Kv channels in 
Jurkat cells. [Fig. 19 C] In this experiment, cells were incubated with FITC-conjugated 
HR-crotamine (1 µM) and increasing concentrations (0 µM to 20 µM) of CP-339818. 
After a 30 min incubation on ice, cells were washed, fixed and cell-bound fluorescence 
determined by flow cytometry as described previously. For these experiments SKF-
96365, a Ca+2 channel inhibitor with no know interactions with Kv channels served as 
the negative control. The results of this experiment [Fig. 19 C] showed clearly a dose-
dependent inhibition of HR-crotamine binding by the Kv channel inhibitor but not by the 
Ca+2 channel inhibitor. This study confirms independently that endogenous Kv channels 
serve as the targets for HR-crotamine binding and further suggest that CP-339818 which 
is known to inhibit Kv channel activity by occluding the extracellular component of K+ 







Fig. 19. Effect of Knockdown/Inhibition of Endogenous Kv channels on HR-
crotamine binding to Jurkat cells 
A) Knockdown efficient test Two shRNA’s for each of the targeted genes (Kv1.1, Kv1,2, 
Kv1.3 and Kv1.5) were cloned into an inducible lentivirus expression system (for 
experimental details see Methods h. Knockdown of Kv Channels in HR-crotamine 
sensitive cells). Jurkat cells were transfected with the expression vectors and transfected 
cells were selected with puromycin. Jurkat cells transfected with the same vector 
containing scrambled shRNA sequences served as a negative control. After 72hr of 
doxycycline induction, cells were harvested for RNA isolation and transcript 
quantification. The level of each Kv channel transcript in control and shRNA transfected 
cells was determined using real-time PCR with gene-specific primers. Transcript levels 
were normalized to the GAPDH internal references and the efficiency of knockdown 
was scaled to the level of expression of the transcript in control cells. Results are the 
mean+/-standard deviation of triplicate determinations B) Binding of HR-crotamine to 
Kv knockdown Jurkat cells Kv channel transcripts in Jurkat cells were knocked down by 
transfection with an inducible lentiviral shRNA expression system for Kv1.1, Kv1.2, 
Kv1.3 and Kv1.5.  Jurkat cells transfected with a scrambled shRNA vector served as the 
control. HR-crotamine binding was determined by incubation with FITC-conjugated 




(Fig. 19. Continued) 
mean+/- standard deviation of triplicate determinations. C) Effect of a Kv channel-
specific inhibitor on HR-crotamine binding to Jurkat cells Jurkat cells were incubated 
with FITC-conjugated HR-crotamine (1 µM) and increasing concentrations CP-339818, 
a Kv1.3 channel inhibitor or SKF-96365, calcium channel inhibitor that served as a 
control. The inhibition of binding curve was generated by curve fitting to the data points. 
Results represent the mean +/-standard deviation of triplicate replications.  
 
Discussion 
The results we have obtained on the direct binding of HR-crotamine to Kv 
channels expressed on the surface of Jurkat cells fits nicely with previous patch clamp 
data that reported that crotamine, a related myotoxin, can inhibit the conductance of the 
Kv1.1, Kv1.2 and Kv1.3 channels but not of Kv1.5 channel (S. Peigneur et al., 2012).   
The studies we carried out using the overexpression of Kv channels in Jurkat 
cells demonstrated the ability of HR-crotamine to bind to Kv1.1, 1.2 and 1.3 but not the 
closely related to Kv1.5. The results obtained by comparing the myotoxin binding 
activity of full-length versus a truncated Kv1.3 expression construct suggested strongly 
that expression on the surface of the cell is a necessary pre-requisite for myotoxin 
binding although we cannot rule out the possibility that the simple mis-folding of the 
truncated protein may have abolished its crotamine binding activity.  
The studies that manipulated the level or activity of the endogenous Kv receptors 
on Jurkat cells provide strong evidence that these proteins are very likely to play a 
critical role as the targets for the anti-proliferative activity of myotoxins in these cells. 
There is extensive evidence in the literature that  the Kv1.1 and Kv1.2 channels play a 
critical role in the transmission of electrical in excitable cells.(Hyun et al., 2015; Perez-




thought to play a much more important role in the regulation of cell cycle activity and 
cell proliferation, particularly in T-cells. These observations provide a solid basis for our 
hypothesis that targeted interactions of HR-crotamine with the endogenous Kv1.3 
channel in T-cell leukemia cells, such as Jurkat cells, may play a crucial role in the anti-
proliferative activity of the toxin. 
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CHAPTER III  




Potassium channels are widely distributed in cells and tissues and have diverse 
electrophysiological and biologic functions (Littleton & Ganetzky, 2000). In the most 
general sense, all potassium channels function to allow the conductance of potassium ion 
down their electrochemical gradient (Hille, 2001) maintaining or adjusting the resting 
membrane potential. At the most basic level the function of potassium channels is 
involved in neural conduction, the maintenance of vascular tone and cardiac contraction 
and multiple secretory processes such as insulin secretion (Checchetto et al., 2013). A 
specific member of the potassium channel family, Kv1.3 channel (encoded by the 
KCNA3 gene) plays a unique role in the regulation of T-cell and B-cell function and 
proliferation. 
  There are a large number of different types of potassium channels that can be 
grouped into four major classes: i) the calcium-activated potassium channels, ii) the 
inwardly rectifying potassium channel,  iii) the tandem pore domain potassium channels 
and iv) the voltage-gated potassium channels (Rang, 2006). Our studies on the biological 
activity of snake venom myotoxins such as HR-crotamine and their membrane targets 
have focused on their interactions with the voltage-gated potassium channel (Kv). The 




expressed in most cells and tissue where they play a vital role in the signal transmission 
and the conduction of action potentials through excitable cells such as neurons and 
various types of muscle cells (Curran, Landes, & Keating, 1992; Gutman et al., 2005).  
As mentioned previously, Kv 1.3 channel, encoded by the KCNA3 gene, has a 
unique role in regulating the immunologic and proliferative activity of T- and B-cells. 
Kv1.3 channel is classified as a member of the delayed rectifier (slowly inactivating) 
family of potassium channel related the “shaker” gene in Drosophila. Shaker gene 
mutations cause of host of neurological and physiological anomalies in fruit flies. In T- 
and B-cells much of the activity of Kv1.3 channels are related to its close coupling to the 
electrochemical systems that control transmembrane Ca+2 flux and the intracellular 
concentration of Ca+2. In lymphocytes, the Kv1.3 channel is only expressed in the G1/S 
stage of the cell cycle (Comes et al., 2013). During this transient period, the Kv1.3 
channel acts in concert Ca+2-activated potassium channel, Kca3.1 to maintain the 
membrane potential during the early stage of cell proliferation (Chiang et al., 2017). The 
resting cell, the cytoplasmic Ca+2- level is about 0.1 µM (in the face of an extracellular 
Ca+2 concentration of 1000 µM). Calcium influx into the cytoplasm of T-cells and B-
cells occurs through the CRAC/ORAI1 channel. The driving force for this influx is the 
large negative intracellular potential (about -60 mV), which is continuously maintained 
by the Kv1.3 channel. The Kv1.3 channel functions to allow for potassium ion efflux out 
of the cell in order to compensate for the depolarizing effect of calcium influx. Once 
cytoplasmic Ca+2 levels reach 1 µM, or higher, the Ca+2 concentration is sufficient to 




dependent protein phosphatase. Activated calcineurin will dephosphorylate the 
transcription factor—NFAT and dephosphorylated NFAT translocate to the nucleus and 
control the transcription for cell proliferation-related genes (Bradding & Wulff, 2009). 
Therefore, through NFAT pathway, the Kv channel’s activity can directly control the 
activation and proliferation of both T-cells and B-cells. [Fig. 20 A, B] 
Our observation that HR-crotamine targets KV channels and Kv1.3 in particular, 
is not unique. There are numerous toxins that have been identified in the venoms of 
many different types of venomous creatures, that have been found to target this channel. 
For instance, several scorpion toxins, including ADWX1, OSK1, margatoxin, kaliotoxin, 
charybdotoxin, noxiustoxin, anuroctoxin as well as some sea anemone toxins including 
ShK family and BgK toxin have been shown to function as Kv channel inhibitors. In 
addition, several chemical compounds, including CP339818, PAP-1, correolide, 
benzamides, progesterone and the anti-lepromatous drug(clofazimine) are also able to 
inhibit the Kv1.3 channel with different degrees of specificity and potency (Garcia-
Calvo et al., 1993; Han et al., 2008; Nguyen et al., 1996). Some of these compounds 







Fig 20. A proposed model for the effect of HR-crotamine’s on calcium influx in T- 
and B- cell lymphocytes 
A) Calcium mediated signaling pathways The figure illustrates the function of Kv1.3 as 
an indirect regulator of proliferation-related calcium signaling pathways in cells. B) The 
proposed effect of HR-crotamine dependent inhibition of Kv1.3 activity on calcium 
mediated signaling pathways, A proposed model for the consequences of HR-crotamine 




(Fig. 20. Continued) 
Inhibition of Kv1.3 is hypothesized to prevent membrane hyperpolarization and thereby 
reduce calcium influx resulting in a lower level of intracellular calcium ion 
concentration. As a consequence, calcium-dependent activation of calmodulin is 
suppressed, resulting in reduced calcineurin activation. Decreased activation of 
calcineurin results in persistent NFAT phosphorylation and a resulting decrease in the 
translocation of NFAT into the nucleus. Decreased NFAT activity decreased the 
expression of proliferation-related genes and an inhibition of cell proliferation.  
 
To explain our observation of the anti-proliferative activity of HR-crotamine in 
Jurkat cells, we hypothesize that as an inhibitor of Kv1.3 activity, HR-crotamine, will 
prevent membrane hyperpolarization and thereby decrease calcium influx. The net effect 
will be a blunting of the calcium-calmodulin-calcineurin-NFAT regulatory system and a 
down regulation in the transcription of genes essential for lymphocyte proliferation. [Fig. 
20 B] The Kv1.3 channel has also been reported to be expressed in mitochondria where 
it is thought to play a role in mitochondrial membrane polarization. There have been 
suggestions that malfunctioning of mitochondrial Kv1.3 channels could be linked to the 
induction of the NOS-mediated cell apoptosis in malignant cell (Cirrone et al., 2017; 
Leanza et al., 2017). We do not think this potential cytotoxic mechanism plays a role in 
the effects of HR-crotamine in Jurkat cells since we have seen no evidence that HR-
crotamine gains access to the interior of Jurkat cells and no evidence that HR-crotamine 
induces either apoptosis or necrosis under the conditions used in our studies. Our 
mechanistic hypothesis related entirely to the anti-proliferative effect of the myotoxin in 
Jurkat cells, and by extension, in lymphocytes.  
 In this chapter, we will test the validity of our hypothesis by investigating the 




will compare the activity of HR-crotamine with well-established Kv1.3 channel inhibitor 
to understand the common points and the variances in their property. In the end, our goal 
is to establish the overall mechanism by which HR-crotamine, and by extension other 
myotoxins, act as anti-proliferative agents in lymphoid cells.   
 
Material and Methods 
Cell culture condition 
Jurkat cell and Jurkat-Lucia™ NFAT Cells were cultured in RPMI complete 
media as described in Chapter I. HEK293T cell were cultured in DMEM complete 
media with the same culture conditions as Jurkat cells. The Jurkat and Jurkat-Lucia™ 
NFAT cells model with Kv channels knockdown was established as described in the 
Method h. Knockdown of Kv Channel in HR-crotamine sensitive cell lines in Chapter II. 
 
Western blot for biomarkers of apoptosis and cell growth inhibition 
Western blot analysis was used to detect biomarkers of apoptosis. Cells were 
treated with 1 µM of HR-crotamine for 24 hr and harvested after a PBS wash step. In 
parallel, cells treated with PBS only were used as a negative control while cells treated 
with 1 µM Etoposide was used as a positive control. Cells were lysed by SDS-PAGE 
loading buffer and the protein samples were denatured and reduced by heating in the 
presence of DTT at 95oC for 5 min. The samples were then loaded onto 4%-12% 
gradient SDS-PAGE gels and then electrophoresed at 150 volts for 40 min. Proteins 




blocked with 5% W/V dry milk for 2 hr and the target protein, cleaved Caspase-3, was 
detected using mouse anti- cleaved Caspase-3 antibody (at 1:1000 dilution). An HRP 
conjugated secondary rabbit anti-mouse antibody (1:5000 dilution) and ECL buffer was 
used to detect the bound anti- cleaved Caspase 3 antibody. The membrane was imaged 
with a Bio-rad ChemiDoc XRS+ system. The level of beta-actin in each sample was also 
visualized with an anti-actin antibody to ensure the equal cell extract loading in each 
sample. 
 
Cell cycle analysis 
To measure cell doubling times, Jurkat, HeLa and SK-Mel-28 cells were diluted 
to 1 x106cells/ml and then loaded with CellTrace™ Far Red (ThermoFisher Scientific, 
MA) following the vendor’s suggested protocol. The adherent cells were then plated and 
allowed to attach while the Jurkat cells were maintained in suspension culture. Cells 
were then incubated with HR-crotamine at multiple concentration (2 µM, 1 µM, 500 nM, 
250 nM and 100 nM), 20µM SKF-96365 (negative control) or 10 µM CP-339818 
(positive control). After 72 hr incubation, the cells were harvested and fixed for flow 
cytometry analysis. The results generated by the flow cytometer was analyzed with 
Flowjo software.  
As an independent measure of cell cycle, we used the expression of P21 
(measured by Western blot) as a biomarker of cell cycle arrest. Cells were pre-incubated 
with 0.5 µM HR-crotamine or 10 µM of CP-339818 (positive control) or PBS (negative 




as described previously. P21 was detected using a mouse anti-P21 antibody (1:2000, 
Cell signaling technology, MA). Beta-actin was used as a reference marker for sample 
loading.   
 
Cell cycle arrest analysis 
A cell cycle arrest analysis was conducted using Propidium Iodide (PI) staining. 
The cells were cultured with HR-crotamine (at 1µM, 0.5 µM, 0.25 µM) or 10 µM CP-
339818(positive control) or PBS (negative control). After 24 hr incubation, cells were 
washed and fixed with 70% ethanol solution and then stained with PI dye prior to flow 
cytometry. The fraction of cell population in G1/S stage and G2/M stage of the cell cycle 
were quantitated with Flowjo software.   
 
Cell viability assay with Kv channel knockdown cells  
Jurkat cells with different Kv channel knockdowns were used for the cell 
viability assay. Cells were seeded in 384-well plates at an appropriate density to support 
exponential growth for 72 hr. Medium containing graded concentrations of HR-
crotamine or the positive control (CP-339818) was added to the cells. After 72 hr, cells 
were DAPI (Sigma-Aldrich, MO) stained and imaged in an InCell 6000 system (GE 
healthcare, CT). Cell counts were determined from the images using cell segmentation 
software and the cell counts were used to quantify cell viability. 
The degree of growth inhibition due to various interventions was expressed as 




increase in the PBS-treated control group (expressed as a % inhibition). Dose-dependent 
changes in growth inhibition were used to the IC50 (concentration producing 50% of 
maximal inhibition of cell growth). 
For the time course studies of cell viability, Jurkat cells with Kv channels 
knockdown were counted at 0 hr, 24 hr, 48 hr and 72 hr, based on DAPI staining and 
automated cell counting using cell imaging segmentation.    
 
Intracellular calcium activity analysis 
To measure the activity of intracellular calcium, 5x103 of Jurkat-Lucia™ NFAT 
cells (Invivogen, CA) were pre-incubated with graded concentrations of HR-crotamine 
(0-4 µM, half-fold dilution), 0-40 µM of CP-339818 (as a positive control for Kv1.3 
channel inhibition) and 0-80µM of SKF-96365(as positive control for inhibition of 
calcium influx) for 1hr on ice. PBS served as the negative control. Calcium influx and 
activation of the NFAT/NF-kB pathways were achieved by addition of 30ng/ml phorbol 
myristate acetate (PMA, Sigma-Aldrich, MO) and 1.5 µM ionomycin (Sigma-Aldrich, 
MO). After 12 hr of incubation to allow for luciferase reporter protein expression cells 
were lysed and reporter protein activity was measured on a multi-mode detector plate 
Reader with Bright-Glo™ Luciferase assay system (Promega, WI). Averaged data from 







IL-2 ELISA assay 
Jurkat cells and peripheral blood CD4+ T cells (PBTC) were seeded in U-bottom 
96-well plate at 5X104 cell/well density. After the application of graded concentrations 
of HR-crotamine (0-4 µM) and CP339818(0-40 µM), phytohemagglutinin (PHA) and 
phorbol ester were added to the cells for 24 hr to activate IL-2 expression and secretion. 
Aliquots of cell-free culture media were collected and the IL-2 concentration was 
measured with a Human IL-2 ELISA Kit (Thermo Fisher Scientific, MO) according to 
the manufacturer's protocol. The averaged absorbance values at 550 nm and 450 nm 
from triplicate samples were used to calculate IL-2 concentration based on a standard 
curve obtained in parallel from the same test plate. The final results were normalized to 
with the min/max value of the observation. 
 
Statistical analysis 
The results from the experiments were summarized in mean+/- standard 
deviation format (n>=3). Inhibition or activation curves were generated by appropriate 
curve fitting and the calculation of IC50 and BC50 were conducted by interpolation of 
curve fitted data. Statistical significance (P<0.05) was calculated using a Student’s t-test 









HR-crotamine induces the cell growth inhibition rather than apoptosis 
When we had tested the effect of HR-crotamine on cell growth for 72 hr in 
multiple cell lines (as described in Chapter I), most of the cell lines showed decreased 
cell numbers compared to the negative control. In the cell proliferation assay, the time 
course also provides indirect evidence for the growth inhibitory effect of HR-crotamine. 
To investigate the intracellular mechanism of HR-crotamine activity, we first need a 
direct determination of HR-crotamine’s growth inhibitory activity and a direct 
demonstration as to whether or not there is any evidence of HR-crotamine – induced   
apoptosis or cell death. The activations of Caspase-3 is a widely utilized biomarker of 
apoptosis. In normal cells, the cleaved Caspase-3 level and the fraction of cleaved 
Caspase-3 positive cells should be very low. In apoptotic cells, there will be a significant 
accumulation of cleaved Caspase-3 that can be observed by either immunoblot of the 
protein or biomarker staining for cleaved Caspase-3 positive cells. To confirm our 
previous conclusion that HR-crotamine did not induce apoptosis in Jurkat cells, the cells 
were treated for 24 hr with graded concentrations of HR-crotamine or Etoposide (serving 
as a positive control) and then the level of cleaved Caspase-3 in cell extracts was 
detected by Western blot analysis. [Fig. 21 A] The results of this experiment showed 
clearly that while the positive control (Etoposide) showed a major cleaved Caspase-3 
band there was no evidence for any induction of apoptosis in Jurkat cells under the 





Effect of HR-crotamine on cell cycle  
Cell growth inhibition is generally reflected in a longer doubling time reflecting a 
delay in progression through the cell cycle. We used cells CellTrace™ proliferation 
assay to investigate the effect of HR-crotamine on cell cycle kinetics in Jurkat cells.  In 
this assay, T0 cells are loaded with the DNA dye-CellTrace™ and extracellular dye is 
then removed by washing. During subsequent cell cycles, the dye loaded cells will 
synthesize the half of their DNA strands with new dNTP molecule resulting in a half 
fold dilution of the dye-labelled DNA for each subsequent cell cycle. Using this method, 
the number of completed cell generations can be measured by analyzing the fluorescent 
intensity of the cell and the percentage of the cell in each generation (ie. the fraction of 
cells that have undergone replication) can be determined. [Fig. 21 B] The results of this 
experiment are that, after 72 hr, the negative control cells (PBS treated only) indicates 5 
peaks with each peak having <50% less fluorescent intensity. By comparison, in cells 
treated with graded concentrations of HR-crotamine, there is clear evidence for a 
reduction in the number of peaks. Cells treated with 1 µM and 2 µM of HR-crotamine 
show only one peak, indicating a complete arrest of proliferative activity in these cells. 
Cells treated 0.5 µM and 0.25 µM HR-crotamine show some evidence of proliferative 
activity but much less than the control. In the 0.5 µM HR-crotamine treated cells, two 
generations of cell proliferation can be observed; and in 0.25 µM HR-crotamine treated 
cells, three generations of proliferation are detected. Cells treated with 0.1 µM HR-
crotamine are very similar to the control cells, indicating very little inhibitory effect on 




blocker, demonstrate only one peak of fluorescent labelling, indicating a complete 
inhibition of cell proliferation. The right-side panel in Fig. 21 B summarizes the effects 
of HR-crotamine (0.5 µM) and 10 µM of CP-339818, compared to control at T0, T24, T48 
and T72 hours. The results show clearly the statistically significant effect of HR-
crotamine on the proliferative activity of the Jurkat cells.  
 As an independent test for the anti-proliferative activity of HR-crotamine in 
Jurkat cells we used a biochemical biomarker assay, the induction of P21 protein, to test 
whether the HR-crotamine induced interference with cell proliferation was reflected in 
the induction of a critical inhibitor of cell cycle progression. P21 inhibits E/CDK2, 
D/CDK4,6 and ICBP90 to arrest cells at G1 stage; it also inhibits Cdc2 to arrest cells in 
G2. P21 also arrests cells in the G1/S boundary by inhibiting or interfereing with the 
expression/activation of A/CDK1,2, NFkB, D, E/CDK2,6, D1 and CDK2,4/cyclin D, E.  
P21 accumulation is a generally accepted biomarker for cycle arrest in most types of 
proliferating cells. We therefore measured the level of P21 expression in cells treated 
with CP-339818 (a positive control for Kv1.3 inhibition) and graded concentrations of 
HR-crotamine. [Fig. 21 C] The results obtained demonstrated a marked increase in the 
cells treated with CP-339818 and a dose-dependent increase in the level of P21 in the 
HR-crotamine treated cells. The estimated for the induction of P21 which is 0.25-0.5 µM 
matches the estimated EC50 for the inhibition of cell cycle progression estimated by the 
dye dilution assay. 
Delayed progression could reflect a generalized slow-down in proliferative 




address this issue, we used Propidium Iodide to stain cellular DNA and then used flow 
cytometry and Flowjo analysis to quantitate the fraction of the cells in G1, S or G2 
phases of the cell cycle. [Fig. 21 D] In the control cells (PBS treated), the majority of 
cells are in G1 (43.8%) with smaller fractions in S and G2 (30.8% and 25.3% 
respectively). Inhibition of Kv1.3 by CP-339818, results in a reciprocal increase in the 
fraction of cells in G1 (67.0%) and a decrease of cells in S phase (9.2%). The fraction of 
cells in G2 is not much affected. These results demonstrate that the Kv1.3 inhibitor 
introduces a block in the G1 to S phase transition. The graded concentrations of HR-
crotamine have a dose- dependent effect very similar to the effect of CP-339818. Graded 
concentrations of the myotoxin progressively increase the number of cells in G1 and 
produce a reciprocal inhibition in the fraction of cells in S-phase. There is little effect on 
the fraction of cells in G2. These results demonstrate clearly that HR-crotamine delays 
cell proliferation by inducing a G1/S phase block in cell cycle progression. The location 
of this blockade is entirely in line with its presumed mechanism of action as a Kv1.3 
inhibitor. In Jurkat cells, it has been previously established that the expression of Kv1.3 
is cell cycle dependent with the protein being transiently expressed at the later stages of 
G1 (Hu et al., 2012). It is thought that the transient expression of the channel protein 
results in a transient hyperpolarization of the membrane potential this increase calcium 
influx. This transient calcium signal is thought to play a role in progression of the cell 
through the G1/S phase boundary. In this model, inhibition of Kv1.3 activity, either by a 




and delay progression of the cells through the boundary, thereby decreasing the 
proliferative rate of the cells.  
 
Fig. 21. The effects of HR-crotamine on the proliferative and apoptotic activity of 
Jurkat cell  
A)Western blot analysis of cleaved Caspase-3 protein levels in HR-crotamine treated 
Jurkat cells Jurkat cells were treated with increasing concentrations of HR-crotamine or 
Etoposide (positive control) for 24 hr and the levels of activated Caspase-3 detected by 
Western blot analysis (see Methods-b. Western blot procedure of markers of cell 
proliferation and apoptosis using anti-cleaved human Caspase-3 antibody (1:2000 




(Fig. 21. Continued) 
cells were loaded with CellTracer (far red) dye at T0 and then were treated with graded 
concentrations of HR-crotamine (0.1-2 µM) or 20 µM CP-339818 (a positive control for 
Kv1.3 inhibition) for 72 hr followed by flow cytometric analysis. (for details see 
Methods c. Cell Cycle Analysis) The green peaks for each cell generation was calculated 
by Flowjo analysis and the generation numbers were marked on the top of peak. The 
mathematically smoothed model for the distribution of fluorescent cells was represented 
by the red line. a) negative control, untreated cells b) positive control, cells  treated with 
20 µM CP-339818, c) cells treated with 2 µM HR-crotamine, d) cells treated with 1 µM 
HR-crotamine, e) cells treated with 0.5 µM HR-crotamine, f) cells treated with 0.25 µM 
HR-crotamine, g) cells treated with 0.1 µM HR-crotamine The panel on right displays 
the replication index (number of cell cycles) for cells treated with PBS(negative control), 
0.5 µM of HR-crotamine and 20 µM of CP-339818(positive control) at T0, T24, T48 and 
T72 hr. Significant decreases in replication index (p<0.05) for HR-crotamine treated cells 
indicated by ** C) Western blot analysis of P21 protein levels in HR-crotamine treated 
Jurkat cells Jurkat cells were treated with increasing concentrations of HR-crotamine or 
10 µM CP-339818 (positive control for Kv1.3 channel inhibition) for 24 hr and the 
levels of activated P21 detected by Western blot analysis (see Methods-b. Western blot 
procedure of markers of cell proliferation) and apoptosis using rabbit anti-human P21 
(1:2000) and an HRP-conjugated anti-rabbit secondary antibody. D) Cell cycle analysis 
of Jurkat cells treated with HR-crotamine  Jurkat cells were treated with increasing 
concentrations of HR-crotamine or 10 µM CP-339818 (positive control for Kv1.3 
channel inhibition) for 24 hr and then were fixed, permeabilized and stained with 
Propidium Iodide to quantitate DNA content (see Methods-d. cell cycle arrest analysis), 
Stained cells were analyzed by flow cytometry and the fraction of cells in G1, S or G2 
phases of the cell cycle were calculated using Flowjo software. Values reflect the 
mean+/-standard deviation for triplicate determinations.  
 
The HR-crotamine’s effect on the Jurkat cell can be affected by Kv channel knockdown   
Our previous studies had suggested that the effects of HR-crotamine’s activity in 
Jurkat cells was focused on the inhibition of Kv1.3 activity. We tested the dependence of 
Jurkat cells proliferation on Kv1.3 in two ways, both by evaluation the activity of a 
specific Kv1.3 channel inhibitor and knocking down the level of expression of Kv1.3 
using an inhibitory shRNA construct. The results are summarized in Fig. 22 A and B.  A 
quantitative evaluation of the activity of the specific Kv1.3 inhibitor CP-339818 [Fig. 22 




in a complete inhibition of Jurkat cell proliferative activity. Since Jurkat cells express 
multiple Kv channel proteins, this result suggests that there is no redundancy among 
these channels and that Jurkat cells are absolutely dependent on Kv1.3 activity for 
proliferation. The results of the experiments with the Kv channel knockdown cell lines 
further support this conclusion. [Fig. 22 B] Reduction in the level of Kv1.3 expression 
(an 80 % reduction in transcript as estimated by qPCR-Fig. 19 B) resulted in a major 
reduction in proliferative activity without complete growth inhibition. This effect was 
entirely specific for Kv1.3, comparable reductions in the level of expression of Kv1.1, 
Kv1.2 and Kv1.5 had no effect on the proliferative activity of the Jurkat cells. These 
observations support the contention that Kv1.3, as distinct from other Kv channels, plays 
a critical role in supporting Jurkat cell proliferation. 
The fact that the Kv1.3 knockdown cells retain a reduced level of proliferative 
activity suggest that, if the reduced proliferative activity is due to residual Kv1.3 (due to 
incomplete knockdown) then further addition of either HR-crotamine or CP-339818 
should result in a complete inhibition of proliferative activity. [Fig. 22 C and Fig. 22 D] 
In the control cells (scrambled vector transfected), HR-crotamine caused a well defned 
dose dependent decrease in proliferative activity with an EC50 of approximately 0.2 µM. 
[Fig. 22 C] In the Kv1.3 channel knockdown cells, the basal rate of proliferation is 
reduced to about 40% of the control value but addition of HR-crotamine causes a clear 
dose-dependent decrease in proliferation to 20% or less of the control value. The IC50 for 
the inhibitory activity of HR-crotamine in Kv1.3 channel knockdown cells (400 nM) is 




target the same HR-crotamine receptor, CP-339818 also reduced the residual 
proliferative activity in Kv1.3 specific targeted shRNA transfected Jurkat cells. In both 
control and Kv1.3 knockdown cells, the highest concentrations of CP-339818 actually 
reduce the cell number below baseline, suggesting some cytotoxic activity with very 
high levels of the compound. Whether this cytotoxic activity is related to the Kv1.3 
inhibitory activity of the chemical compound or is due to some low affinity “off-target” 
effect from very high concentrations of the drug is not known. 
 
 
Fig. 22. Effect of Inhibition and knockdown of Kv channels on the proliferative 
activity and their sensitivity to HR-crotamine of Jurkat cells 
A) Effect of Kv inhibitor CP-339818 on the proliferative activity of Jurkat cells. The 
activity of the Kv1.3 channel in Jurkat cells was suppressed using graded concentrations 
(100 µM, 25 µM, 12.5 µM) of CP-339818 (for experimental methods see Chapter III 




(Fig. 22. Continued) 
of the treated cells is compared to the PBS control. Each data point represents mean+/- 
standard deviation for 4 replicate determinations. B) Effect of Kv channel knockdown on 
the proliferative activity of Jurkat cells. The expression of Kv channels in Jurkat cells 
was suppressed using an inducible lentiviral expression system containing shRNAs for 
Kv1.1, Kv1.2, Kv1.3 and Kv1.5 (for experimental methods see Chapter II Methods h. 
Knockdown of Kv channel in HR-crotamine sensitive cell lines and Fig 19. B and 
Chapter III Methods h. Cell Viability with Kv Channel Knockdown Cells) The 
proliferative activity of the knockdown cell lines is compared to the control line (Jurkat 
cells transfected with the scrambled shRNA construct) cell lines. Each data point 
represents mean+/- standard deviation for 4 replicate determinations. C) Effect of HR-
crotamine on the proliferative activity of Kv1.3 channel knockdown Jurkat cells Jurkat 
cells transfected with the Kv1.3 knockdown construct (Kv1.3 shRNA) or control cells 
(scrambled shRNA) were treated with graded concentrations of HR-crotamine for 72 
hours. Cell proliferation was measured by cell counting as described in Chapter III 
Methods h. Cell Viability with Kv Channel Knockdown Cells, each data point represents 
mean+/-standard deviation for 4 replicate determinations. D) Effect of CP-339818 on the 
proliferative activity of Kv1.3 knockdown Jurkat cells Jurkat cells transfected with the 
Kv1.3 knockdown construct (Kv1.3 shRNA) or control cells (scrambled shRNA) were 
treated with graded concentrations of CP-33918 for 72 hr. Cell proliferation was 
measured by cell counting as described in Chapter III Methods h. Cell Viability with Kv 
Channel Knockdown Cells. Each data point represents mean+/- standard deviation for 4 
replicate determinations. 
 
Effect of HR-crotamine on calcium signaling in Jurkat cells and lymphocytes 
There are published reports that Kv1.3 channels may play an important role in 
the regulation of membrane potential and calcium influx in non-excitable cells such as 
lymphocytes(Fung-Leung et al., 2017; Newell & Schlichter, 2005). It is thought that 
through the combined activity of Kv1.3 channel and KCa3.1 channel, membrane potential 
can be preserved when the CRAC/ORAI channels open to allow for transmembrane 
calcium influx. It is thought that transient calcium influx during cell cycle progression 
plays a critical role in regulating cell proliferation (Hogan, Lewis, & Rao, 2010). To test 
this in our Jurkat cells, we examined the effect of graded concentrations of SKF-96365, 




results obtained [Fig. 23 A] showed clearly that inhibition of calcium influx in Jurkat 
cells has a profound inhibitory effect on cell proliferation. The next step in testing our 
hypothesis on the mechanisms that mediate the effects of HR-crotamine on cell 
proliferation was to determine whether exposure to HR-crotamine modifies calcium 
influx into cells, as reflected in the activation of a calcium-dependent reporter system. 
We have used a Jurkat cell line containing a stably integrated NFAT-inducible Lucia 
reporter construct (Jurkat-Lucia™ NFAT cells). In this construct, the Lucia gene, which 
encodes a secreted coelenterazine-utilizing luciferase, is fused to six copies of the NFAT 
consensus transcriptional response element. Calcium influx-induced translocation of 
NFAT can be quantitatively measured by the increased expression of the Lucia reporter 
transcript product and the increase in Lucia luciferase enzymatic activity. The results of 
this experiment showed that HR-crotamine produced a clear dose-dependent reduction in 
luciferase activity reflecting an almost complete inhibition of calcium signaling at the 
highest concentration tested. [Fig. 23 B] The activity of HR-crotamine was paralleled by 
CP-339818 and SKF-96365 demonstrating that HR-crotamine’s inhibitory activity was 
comparable to an established Kv1.3 inhibitor and a drug that blocked transmembrane 
calcium influx in these cells. [Fig. 23 C and Fig. 23 D] We also tested whether 
knockdown of any of the other Kv channels in Jurkat cells had a similar effect on 
transmembrane calcium influx and cell signaling. [Fig. 23 E and Fig. 23 F] The results 
obtained from these studies showed that Kv1.3 was the only Kv channel in Jurkat cells 
whose knockdown resulted in a decrease (>80%) in trans-membrane signaling and 




small but consistent further reduction in trans-membrane calcium influx and signaling. 
[Fig. 23 C and Fig. 23 D] The results of these studies show clearly that HR-crotamine 
functions as an indirect inhibitor of calcium influx through the SOCE calcium entry 
system. 
 
Fig. 23. HR-crotamine’s effect on intracellular calcium activity 
A) Analysis of effect on cell cycle kinetics of SKF-96365 in Jurkat cells. Jurkat cells 
were loaded with CellTracer (far red) dye at T0 and then were treated with graded 
concentrations of SKF-96365, a STIM1 inhibitor that blocks the activity of Store-
operated Ca2+ entry (SOCE) for 72 hr followed by flow cytometric analysis. (for details 
see Methods c. Cell Cycle Analysis) The green peaks for each cell generation was 
calculated by Flowjo analysis and the generation numbers were marked on the top of 
peak. The mathematically smoothed model for the distribution of fluorescent cells was 
represented by the red line. In the Figure i) Negative Control (buffer only); ii) SKF-
96365 0.6 µM; iii) SKF-96365 1.25 µM; iv) SKF-96365 10 µM.  Panel on Right 
displays the replication index (number of cell cycles) for cells treated with PBS buffer 
(control), or SKF-96365 1.25 µM at T0, T24, T48 and T72 hr. Significant decreases in 










(Fig. 23. Continued) 
 
B) Effect of HR-crotamine on the activity of an intracellular calcium reporter system in 
Jurkat-Lucia NFAT cells Jurkat-Lucia NFAT cells were treated with graded 
concentrations of HR-crotamine (10 nM-2 µM), SKF-96365 (a positive control for 
inhibition of calcium influx and CP-339818 (a positive control for Kv1.3 inhibition) for 
1 hr on ice (under conditions described in Methods i. Intracellular calcium activity 
analysis). Calcium influx and activation of the NFAT/NF-kB pathways were achieved 
by addition of 30 ng/ml phorbol myristate acetate and 1.5 µM ionomycin followed by 
incubation for 12 hr subsequent analysis of luciferase activity in cell lysates.  C) Effect of 
HR-crotamine on the activity of an intracellular calcium reporter system in Kv1.3 
knockdown Jurkat-Lucia NFAT cells Control Jurkat-Lucia NFAT cells (transfected with 




(Fig. 23. Continued) 
with an inducible lentivirus shRNA vector containing two different Kv1.3 inhibitory 
shRNAs) were treated with 0.5 µM HR-crotamine or buffer control and calcium activity 
was measured by activation of the luciferase reported gene as described Methods i. 
Intracellular calcium activity analysis and the legend to Fig. 23 B. Values represent the 
mean+/-standard deviation of duplicate determinations. D) Effect of CP-339818 on the 
activity of an intracellular calcium reporter system in Kv1.3 knockdown Jurkat-Lucia 
NFAT cells. Control Jurkat-Lucia NFAT cells (transfected with scrambled shRNAs) and 
2 lines of Kv1.3 knockdown cells (each transfected with an inducible lentivirus shRNA 
vector containing two different Kv1.3 inhibitory shRNAs) were treated with 20 µM CP-
339818 or buffer control; and calcium activity was measured by activation of the 
luciferase reported gene as described Methods i. Intracellular calcium activity analysis 
and the legend to Fig. 23 B. Values represent the mean+/-standard deviation of 4 
replicate determinations E) Effect of HR-crotamine on the activity of an intracellular 
calcium reporter system in a series of Kv knockdown Jurkat-Lucia NFAT cells Control 
Jurkat-Lucia NFAT cells (transfected with scrambled shRNAs) and 2 lines of Kv 
knockdown cells (each transfected with an inducible lentivirus shRNA vector containing 
two different inhibitory shRNAs for Kv1.1, Kv1.2 or Kv1.5) were treated with buffer 
(Control) or 0.5 µM HR-crotamine and calcium activity was measured by activation of 
the luciferase reported gene as described Methods i. Intracellular calcium activity 
analysis and the legend to Fig. 23. B) Values represent the mean+/-standard deviation of 
4 replicate determinations F) Effect of CP-339818 on the activity of an intracellular 
calcium reporter system in a series of Kv knockdown Jurkat-Lucia NFAT cells Control 
Jurkat-Lucia NFAT cells (transfected with scrambled shRNAs) and 2 lines of 
knockdown cells (each transfected with an inducible lentivirus shRNA vector containing 
two different inhibitory shRNAs for Kv1.1, Kv1.2 or Kv1.5) were treated with buffer 
(Control) or 20 µM CP-339818 and calcium activity was measured by activation of the 
luciferase reported gene as described Methods i. Intracellular calcium activity analysis 
and the legend to Fig. 23 B. Values represent the mean+/-standard deviation of 4 
replicate determinations 
 
Calcium influx into T- and B-cells is linked both to cell activation and the 
induction of cell proliferation. To assess the effect of HR-crotamine on the lymphocyte 
activation we have measured the impact of exposure to HR-crotamine on the induction 
of IL-2 secretion. IL-2 secretion is a well-established marker for T-cell activation 
(Bartelt, Cruz-Orcutt, Collins, & Houtman, 2009). For these studies, we have extended 




CD4+ positive peripheral blood T-cells. In both Jurkat and CD4+ T-cells increasing 
concentrations of HR-crotamine resulted in a major inhibition of both T-cell and Jurkat 
cell activation as measured by IL-2 secretion. [Fig. 24 A] This effect mirrored an 
equivalent inhibition of activation produced by exposure of the cells to CP-339818, a 
specific inhibitor of Kv1.3 activity. [Fig. 24 B] An interesting implication of these 
studies is that the inhibition of calcium influx and activation in these two cell types 
reflects the fact that although they share expression of Kv1.3 on their membranes they 
differ in the channels that support calcium entry into the cells. Jurkat cell express 
CRAC/ORAI1 calcium channel and the CD4+ T-cells express CaV1/ORAI1 calcium 
channel. The fact that HR-crotamine inhibits calcium activation in both cell types 
supports the idea that the inhibitory effect of the myotoxin on calcium influx is indeed an 
indirect effect reflecting the inhibition of Kv1.3 channel activity rather than any direct 
effect on the calcium entry pathways.   
 
Fig. 24. Effects of HR-crotamine and CP-339818 on IL-2 secretion by Jurkat and 
CD4+T cells 
A) Effect of HR-crotamine on IL-2 secretion Jurkat cells and peripheral blood CD4+ T 




(Fig. 24. Continued) 
graded concentrations of HR-crotamine (0-12µM). or B) CP-339818 (5-50µM). 
Phytohemagglutinin (PHA) and phorbol ester were added to the cells for 24 hr to 
activate IL-2 expression and secretion as measured by a human ELISA kit (procedures 
described in detail in Methods j. IL-2 ELISA Assay) Values represent the mean+/-




The results from our study indicate that while HR-crotamine binds to multiple 
Kv channels including Kv1.1, Kv1.2 and Kv1.3, its functional activity as an inhibitor of 
the proliferative activity of T-cell leukemia cells is linked specifically to the inhibition of 
Kv1.3 activity. The results we have obtained point to a model in which the inhibition of 
Kv1.3 activity leads indirectly to an inhibition of transmembrane calcium flux and a 
resulting inhibition of calcium-dependent cell signaling. It is ultimately this inhibition of 
cell signaling that results in an inhibition of cell proliferation and lymphocyte activation. 
Furthermore, the interaction appears to occur on the outer surface of the cell on the 
extracellular port for K+ ion flux since the binding of HR-crotamine to the Jurkat cells is 
inhibited by the binding of CP-339818 to the cells (Nguyen et al., 1996; Schmitz et al., 
2005). Once HR-crotamine is bound to the cell surface Kv1.3 channel, it disables 
potassium ion out-flow through the channel. Because the conductance of the Kv1.3 
channel is reduced by crotamine (Steve Peigneur et al., 2012), the resulting decrease in 
membrane polarization interferes with calcium and calcium signaling mediated cell 
activation is halted. As a consequence, the IL-2 secretion was inhibited(Feske, Wulff, & 
Skolnik, 2015; Hogan et al., 2010). Since cell cycle specific calcium influx also plays a 




channel (Munaron, Antoniotti, & Lovisolo, 2004). We believe that the selective and 
differential effects of myotoxins on different normal and malignant cell types are likely 
due to differences in the expression of cell surface Kv1.3 and potentially to differences 
in which the activity of Kv1.3 plays a critical role in regulating calcium influx in 
different types of cell. Under our experimental conditions, the functional effect of Kv1.3 
blockade by HR-crotamine is very specifically linked to anti-proliferative activity. We 
detected absolutely no evidence for the inducting of apoptosis or the penetration of the 
toxin into the body of the cell.  Lastly, we note that very specific effect of HR-crotamine 
in inducing cell cycle arrest at the G1/S boundary matches exactly the temporal pattern 
of expression of Kv1.3 in lymphocytes. It is thought that the transient induction of Kv1.3 
late in G1 leads to a transient spike in calcium influx that promotes the passage of the 
cell past the G1/S checkpoint. By inhibiting this transient calcium spike, it is very likely 
that HR-crotamine inhibits progress of the cell through the cycle and ultimately inhibits 
overall cell proliferation. 
There are reports that the Kv1.3 channel is not only expressed on the surface 
cells but also on the mitochondrial membrane. It has been suggested that malfunction of 
the mitochondrial Kv1.3 channel may trigger NOS-mediated cell apoptosis in the 
malignant cells (Leanza et al., 2017). Presumably penetration of the cell membrane must 
be a necessary prerequisite for any effects of myotoxins on mitochondrial function. In 
our studies, we have not seen evidence that, under the conditions we have used, cell 
penetration either occurs or is a necessary step in HR-crotamine’s biological activity. 




membrane penetrating activity of crotamine(Nascimento et al., 2007; Ponnappan & 
Chugh, 2017). It is possible that the lower levels surface HSPG receptor expression in 
Jurkat cells compared to other attached cells, such as HeLa cell.(Leanza et al., 2017) 
may explain why this particular pathway for biological activity was not detected in our 
studies.   
Our study has established a model that demonstrates a pathway starts with the 
interaction of HR-crotamine with a specific target on the surface of a cell and leads to 
intracellular mechanisms that affects the proliferation and activation of that cell. These 
findings can be considered as the foundation for the future research on how one may be 
able to utilize the selective anti-proliferative effect of HR-crotamine (and crotamine-like 
proteins) to suppress the growth of certain types of the malignant cells. Ultimately, an 
understanding of the structure-function relation for HR-crotamine’s cell specificity and 
toxicity has the potential to be extremely helpful in developing the HR-crotamine into a 
new anti-cancer drug or effective anti-myotoxin antivenom.  
Recent studies in our lab have also pointed to another manifestation of the 
selective activity of HR-crotamine as an inhibitor of biological functions. Working with 
collaborators, we have discovered that HR-crotamine can disorganize the contraction of 
the smooth muscle in the lymphatic vessels. Several pieces of evidence suggest that this 
effect may also reflect inhibition cell surface Kv1.3 activity. Disruption of lymphatic 
vessel contractility may have important implications not only for the treatment of snake 




Our studies have focused on the interactions of HR-crotamine with Kv1.3 
channel since this appears to be the most important functional Kv channel in 
lymphocytes. We recognize that in other cell types, especially excitable cells such as 
neurons and muscle cells, Kv1.1 and Kv1.2 play a critical role in regulating membrane 
potentials. HR-crotamine targeting of these receptors is very likely to play an important 
role in the well documented neurotoxic and myotoxic effects of myotoxins. These 
include spinal cord paralysis as manifest in hind-limb paralysis in small animals as well 
as the myofasciculations and rhabdomyolysis that occurs in humans after envenomation 
with myotoxin contained venoms. (Rizzi et al., 2007)  
 
Further study 
According to our understanding, there is still a long way to go to get the full 
understanding for all of HR-crotamine’s targets and their activities. HR-crotamine is a 
small biotoxin with extremely low immunogenicity. As a consequence, there are no 
commercial or experimental anti-toxins that can effectively block the toxicity of 
myotoxins such as HR-crotamine. The model we have developed may prove to be useful 
in finding new types of molecules that can neutralize the cytotoxicity of HR-crotamine 
and other myotoxins. Our research can provide a reference point and the foundation for 
future investigations designed to screen for potential anti-venom molecules. Specifically, 
the phage display-based screening of single-chain antibody library can be applied to our 
cell testing model and an in vivo test for the effective single chain antibody can be used 




Future screens for potential toxin-binding antibodies will be able to use 
polyclonal phage libraries that can be used to select for HR-crotamine-binding phages 
selected after multiple rounds of bio-panning against HR-crotamine. The specificity of 
phage clones that bind to HR-crotamine will be examined by single-chain variable 
fragment (scFv) ELISA against a panel of structurally related peptides such as human 
beta-defensins or myotoxin III from venom of Bothrops asper. The DNA sequences of 
the scFv obtained from ELISA will be cloned into E. coli for producing soluble scFv 
with an affinity tag for purification propose. The activity of individual scFv will be 
determined with the NFAT luciferase assay, by measuring the ability of each scFv to 
neutralize HR-crotamine’s inhibitory activity without interfering with Jurkat cell 
viability. For these experiments, the Jurkat-Lucia NFAT cells will be incubated with the 
scFv to eliminate any scFv that have cytotoxicity. The protocol for the test with non-
cytotoxic scFv will be same as the NFAT luciferase assay. Some of the most effective 
scFv will be selected to confirm their ability to suppress HR-crotamine’s inhibitory 
effect on IL-2 secretion in Jurkat cells. 
Once we successfully identified the antitoxin with the confirmed toxicity-
neutralization activity, the principle behind our screening strategy will have been proven 
to be successful. Based on the experiences that we acquired through our investigation, 
similar approaches can be applied in the future to the study of other toxins in the 
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CELL SURFACE KV1.3 CHANNEL STAINING 
           
 In Chapter I, we measured the level of Kv1.3 transcripts in HR-crotamine 
sensitive and insensitive cells, to confirm that the level of transcript was correlated with 
the amount of protein expressed on the surface of cells, we measured cell surface Kv1.3 
staining in both Jurkat and C2C12 cells using a FITC conjugated anti-Kv1.3 channel 
antibody coupled with flow cytometric analysis [Fig. AP1]. The rightward of the FITC 
curve in cells treated with the FITC conjugated anti-Kv1.3 channel antibody compared 
to controls in both C2C12 and Jurkat cells confirms the presence of cell surface Kv1.3 
on both cell types. The much larger shift for Jurkat cells, compared to C2C12 cells 
confirms that there is a larger amount of Kv1.3 expressed on the surface of Jurkat 
compared to C2C12 cells, an observation that also correlates with their relative 





Fig. AP1. Cell surface Kv1.3 channel staining.  
Jurkat and C2C12 cells were stained with FITC-conjugated anti-Kv1.3 antibody and 
analyzed by flow cytometry on FITC channel. Blank represents the FITC signal of cell 
without FITC-conjugated anti-Kv1.3 antibody to show the base line of FITC reading. 














OVEREXPRESSION OF THE TAGGED KV CHANNELS  
 
In Chapter I, we have demonstrated the successful overexpression of Kv 
channels in the HeLa cells by Western blot. Meantime, each of the Kv channel 
expression vectors were transfected into HeLa cells and the expression of the channel 
proteins was confirmed by the detection of the mCherry fusion protein by fluorescence 
microscopy [Fig. AP2].   
 
Fig. AP2. Overexpression of the Kv channels in HeLa cells  
Expression of Kv channel-mCherry fusion proteins in transfected HeLa cells.  Kv 
channel expression vectors were transfected into HeLa cells with Lipofectamine 3000 
using the vendor-recommended protocol. After 48 hr, cells were imaged using a 
DeltaVision fluorescent microscope. In the images, the red fluorescence is due to the 






PULL DOWN CONDITION EXPLORATION 
 
Pull down analysis is widely considered as a method that can directly prove the 
protein-protein interaction. According to the preliminary analysis, the Dynabeads M-280 
without immobilized HR-crotamine does not indicate the Kv channel protein binding or 
indicate background level protein binding. This indicates the low background and the 
high reliability of the results from our test groups. The binding and washing condition 
were also tested to optimize the protocol with the maximum contrast between the signal 
and the non-specific background. In the preliminary test, we aimed to achieve the 
condition to produce the best contrast in the Western blot and SDS-PAGE. Different 
binding buffer/ wash buffer combination (with detergent present or absent) was tested. 
The protein samples were extracted from the cytoplasm membrane of HeLa cell 
overexpressed Kv channels and an equal amount of the protein was loaded to the pull-
down system. Based on the result from Western blot, the protein has better binding result 
in PBS buffer compare with TBS buffer. This result may cause by the difference of the 
pH between these two buffers. The detergent can reduce the binding, but the background 
for the control without wash by detergent buffer also has attracted our attention. The 
high salt wash buffer, containing 150 mM NaCl, can reduce the electronic binding as 
well, so the bands indicate the binding is not only electronic charge depend. Refer to 





Fig. AP3. Pull down condition exploration  
The Jurkat cell was transfected with Kv channel overexpression vector (pCIG3 vector). 
The cell membrane protein was prepared by the Membrane Prep kit. In the pull-down 
analysis, the protein was trapped by streptavidin immobilized biotin-HR-crotamine and 
the sample was applied to the Western blot following the conventional protocol. The 
rabbit anti-Flag antibody was used in 1:1000 dilution.  Multiple binding and washing 
condition were tested for the maximum contrast between the specific band and non-
specific background 
 
 
 
 
 
